<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Cardiothorac Surg</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Cardiothorac Surg</journal-id><journal-id journal-id-type="publisher-id">ejcts</journal-id><journal-id journal-id-type="hwp">ejctsurg</journal-id><journal-title-group><journal-title>European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery</journal-title></journal-title-group><issn pub-type="ppub">1010-7940</issn><issn pub-type="epub">1873-734X</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24948413</article-id><article-id pub-id-type="pmc">4324609</article-id><article-id pub-id-type="doi">10.1093/ejcts/ezu238</article-id><article-id pub-id-type="publisher-id">ezu238</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>16</subject><subject>29</subject><subject>31</subject></subj-group><subj-group subj-group-type="heading"><subject>Adult Cardiac</subject></subj-group></article-categories><title-group><article-title>The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Drury</surname><given-names>Nigel E.</given-names></name><xref ref-type="aff" rid="af1">a</xref><xref ref-type="aff" rid="af2">b</xref></contrib><contrib contrib-type="author"><name><surname>Howell</surname><given-names>Neil J.</given-names></name><xref ref-type="aff" rid="af1">a</xref><xref ref-type="aff" rid="af2">b</xref></contrib><contrib contrib-type="author"><name><surname>Calvert</surname><given-names>Melanie J.</given-names></name><xref ref-type="aff" rid="af3">c</xref></contrib><contrib contrib-type="author"><name><surname>Weber</surname><given-names>Ralf J.M.</given-names></name><xref ref-type="aff" rid="af4">d</xref></contrib><contrib contrib-type="author"><name><surname>Senanayake</surname><given-names>Eshan L.</given-names></name><xref ref-type="aff" rid="af1">a</xref><xref ref-type="aff" rid="af2">b</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Michael E.</given-names></name><xref ref-type="aff" rid="af5">e</xref></contrib><contrib contrib-type="author"><name><surname>Hyde</surname><given-names>Jonathan A.J.</given-names></name><xref ref-type="aff" rid="af5">e</xref></contrib><contrib contrib-type="author"><name><surname>Green</surname><given-names>David H.</given-names></name><xref ref-type="aff" rid="af6">f</xref></contrib><contrib contrib-type="author"><name><surname>Mascaro</surname><given-names>Jorge G.</given-names></name><xref ref-type="aff" rid="af1">a</xref></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>Ian C.</given-names></name><xref ref-type="aff" rid="af1">a</xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Timothy R.</given-names></name><xref ref-type="aff" rid="af1">a</xref></contrib><contrib contrib-type="author"><name><surname>Rooney</surname><given-names>Stephen J.</given-names></name><xref ref-type="aff" rid="af1">a</xref></contrib><contrib contrib-type="author"><name><surname>Viant</surname><given-names>Mark R.</given-names></name><xref ref-type="aff" rid="af4">d</xref></contrib><contrib contrib-type="author"><name><surname>Freemantle</surname><given-names>Nick</given-names></name><xref ref-type="aff" rid="af7">g</xref></contrib><contrib contrib-type="author"><name><surname>Frenneaux</surname><given-names>Michael P.</given-names></name><xref ref-type="aff" rid="af8">h</xref></contrib><contrib contrib-type="author"><name><surname>Pagano</surname><given-names>Domenico</given-names></name><xref ref-type="aff" rid="af1">a</xref><xref ref-type="aff" rid="af2">b</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><on-behalf-of>on behalf of the investigators</on-behalf-of><xref ref-type="author-notes" rid="AN1">†</xref><aff id="af1"><label>a</label><addr-line>Department of Cardiothoracic Surgery</addr-line>, <institution>Queen Elizabeth Hospital Birmingham</institution>, <addr-line>Birmingham</addr-line>, <country>UK</country></aff><aff id="af2"><label>b</label><addr-line>School of Clinical and Experimental Medicine</addr-line>, <institution>University of Birmingham</institution>, <addr-line>Birmingham</addr-line>, <country>UK</country></aff><aff id="af3"><label>c</label><addr-line>School of Health and Population Sciences</addr-line>, <institution>University of Birmingham</institution>, <addr-line>Birmingham</addr-line>, <country>UK</country></aff><aff id="af4"><label>d</label><addr-line>Centre for Systems Biology, School of Biosciences</addr-line>, <institution>University of Birmingham</institution>, <addr-line>Birmingham</addr-line>, <country>UK</country></aff><aff id="af5"><label>e</label><addr-line>Department of Cardiothoracic Surgery</addr-line>, <institution>Royal Sussex County Hospital</institution>, <addr-line>Brighton</addr-line></aff><aff id="af6"><label>f</label><addr-line>Department of Cardiac Anesthesia</addr-line>, <institution>Queen Elizabeth Hospital Birmingham</institution>, <addr-line>Birmingham</addr-line>, <country>UK</country></aff><aff id="af7"><label>g</label><addr-line>Department of Primary Care and Population Health</addr-line>, <institution>University College London</institution>, <addr-line>London</addr-line>, <country>UK</country></aff><aff id="af8"><label>h</label><addr-line>School of Medicine</addr-line>, <institution>University of Aberdeen</institution>, <addr-line>Aberdeen</addr-line>, <country>UK</country></aff></contrib-group><contrib-group><contrib contrib-type="collab"><collab>on behalf of the investigators</collab></contrib><contrib contrib-type="collab"><name><surname>Williams</surname><given-names>Lynne K.</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Ranasinghe</surname><given-names>Aaron M.</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Hauton</surname><given-names>David</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Cramb</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Dandekar</surname><given-names>Uday</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Cohen</surname><given-names>Andrew S.</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Kong</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Cooter</surname><given-names>Nina</given-names></name></contrib><contrib contrib-type="collab"><name><surname>Gardner</surname><given-names>Emma</given-names></name></contrib><contrib contrib-type="collab"><name><surname>MacKenzie</surname><given-names>Ailie</given-names></name></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Department of Cardiothoracic Surgery, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, UK. Tel: +44-121-6272850; fax: +<fax>44-121-6272895</fax>; e-mail: <email>domenico.pagano@uhb.nhs.uk</email> (D. Pagano).</corresp><fn id="AN1" fn-type="con"><label>†</label><p>Trial investigators: the authors plus Lynne K. Williams, Aaron M. Ranasinghe, David Hauton, Robert Cramb, Uday Dandekar, Andrew S. Cohen, Robert Kong, Nina Cooter, Emma Gardner, Ailie MacKenzie.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>19</day><month>6</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>6</month><year>2014</year></pub-date><volume>47</volume><issue>3</issue><fpage>464</fpage><lpage>472</lpage><history><date date-type="received"><day>14</day><month>10</month><year>2013</year></date><date date-type="rev-recd"><day>18</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</copyright-statement><copyright-year>2014</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ezu238.pdf"></self-uri><abstract><sec><title><offsets xml_i="9267" xml_f="9277" txt_i="11" txt_f="21">OBJECTIVES</offsets></title><p><offsets xml_i="9288" xml_f="9672" txt_i="22" txt_f="406">Perhexiline is thought to modulate metabolism by inhibiting mitochondrial carnitine palmitoyltransferase-1, reducing fatty acid uptake and increasing carbohydrate utilization. This study assessed whether preoperative perhexiline improves markers of myocardial protection in patients undergoing coronary artery bypass graft surgery and analysed its effect on the myocardial metabolome.</offsets></p></sec><sec><title><offsets xml_i="9694" xml_f="9701" txt_i="408" txt_f="415">METHODS</offsets></title><p><offsets xml_i="9712" xml_f="10159" txt_i="416" txt_f="863">In a prospective, randomized, double-blind, placebo-controlled trial, patients at two centres were randomized to receive either oral perhexiline or placebo for at least 5 days prior to surgery. The primary outcome was a low cardiac output episode in the first 6 h. All pre-specified analyses were conducted according to the intention-to-treat principle with a statistical power of 90% to detect a relative risk of 0.5 and a conventional one-sided </offsets><italic><offsets xml_i="10167" xml_f="10168" txt_i="863" txt_f="864">α</offsets></italic><offsets xml_i="10177" xml_f="10302" txt_i="864" txt_f="989">-value of 0.025. A subset of pre-ischaemic left ventricular biopsies was analysed using mass spectrometry-based metabolomics.</offsets></p></sec><sec><title><offsets xml_i="10324" xml_f="10331" txt_i="991" txt_f="998">RESULTS</offsets></title><p><offsets xml_i="10342" xml_f="10648" txt_i="999" txt_f="1305">Over a 3-year period, 286 patients were randomized, received the intervention and were included in the analysis. The incidence rate of a low cardiac output episode in the perhexiline arm was 36.7% (51/139) vs 34.7% (51/147) in the control arm [odds ratio (OR) 0.92, 95% confidence interval (CI) 0.56–1.50, </offsets><italic><offsets xml_i="10656" xml_f="10657" txt_i="1305" txt_f="1306">P</offsets></italic><offsets xml_i="10666" xml_f="10793" txt_i="1306" txt_f="1433"> = 0.74]. Perhexiline was associated with a reduction in the cardiac index at 6 h [difference in means 0.19, 95% CI 0.07–0.31, </offsets><italic><offsets xml_i="10801" xml_f="10802" txt_i="1433" txt_f="1434">P</offsets></italic><offsets xml_i="10811" xml_f="10904" txt_i="1434" txt_f="1527"> = 0.001] and an increase in inotropic support in the first 12 h (OR 0.55, 95% CI 0.34–0.89, </offsets><italic><offsets xml_i="10912" xml_f="10913" txt_i="1527" txt_f="1528">P</offsets></italic><offsets xml_i="10922" xml_f="11197" txt_i="1528" txt_f="1803"> = 0.015). There were no significant differences in myocardial injury with troponin-T or electrocardiogram, reoperation, renal dysfunction or length of stay. No difference in the preischaemic left ventricular metabolism was identified between groups on metabolomics analysis.</offsets></p></sec><sec><title><offsets xml_i="11219" xml_f="11230" txt_i="1805" txt_f="1816">CONCLUSIONS</offsets></title><p><offsets xml_i="11241" xml_f="11537" txt_i="1817" txt_f="2113">Preoperative perhexiline does not improve myocardial protection in patients undergoing coronary surgery and in fact reduced perioperative cardiac output, increasing the need for inotropic support. Perhexiline has no significant effect on the mass spectrometry-visible polar myocardial metabolome </offsets><italic><offsets xml_i="11545" xml_f="11552" txt_i="2113" txt_f="2120">in vivo</offsets></italic><offsets xml_i="11561" xml_f="11774" txt_i="2120" txt_f="2333"> in humans, supporting the suggestion that it acts via a pathway that is independent of myocardial carnitine palmitoyltransferase inhibition and may explain the lack of clinical benefit observed following surgery.</offsets></p></sec><sec><title><offsets xml_i="11796" xml_f="11817" txt_i="2335" txt_f="2356">ClinicalTrials.Gov ID</offsets></title><p><offsets xml_i="11828" xml_f="11840" txt_i="2357" txt_f="2369">NCT00845364.</offsets></p></sec></abstract><kwd-group><kwd>Cardiac output</kwd><kwd>Metabolism</kwd><kwd>Metabolomics</kwd><kwd>Myocardial reperfusion injury</kwd><kwd>Myocardial stunning</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title><offsets xml_i="12089" xml_f="12101" txt_i="2378" txt_f="2390">INTRODUCTION</offsets></title><p><offsets xml_i="12112" xml_f="12273" txt_i="2391" txt_f="2552">The population of patients undergoing cardiac surgery is becoming older, with more comorbidities and complex patterns of disease, requiring more urgent surgery [</offsets><xref rid="EZU238C1" ref-type="bibr"><offsets xml_i="12310" xml_f="12311" txt_i="2552" txt_f="2553">1</offsets></xref><offsets xml_i="12318" xml_f="12539" txt_i="2553" txt_f="2774">]. Such factors are often associated with abnormal myocardial metabolism and may contribute towards increasing the length of ischaemic arrest, which remains an independent predictor of mortality in contemporary practice [</offsets><xref rid="EZU238C2" ref-type="bibr"><offsets xml_i="12576" xml_f="12577" txt_i="2774" txt_f="2775">2</offsets></xref><offsets xml_i="12584" xml_f="12966" txt_i="2775" txt_f="3157">]. With current techniques for myocardial protection using blood cardioplegia, up to 30% of patients have a period of clinically detectable transient dysfunction due to myocardial stunning. An episode of non-fatal low cardiac output in the early postoperative period is associated with a significant reduction in late survival following coronary artery bypass graft (CABG) surgery [</offsets><xref rid="EZU238C3" ref-type="bibr"><offsets xml_i="13003" xml_f="13004" txt_i="3157" txt_f="3158">3</offsets></xref><offsets xml_i="13011" xml_f="13312" txt_i="3158" txt_f="3459">] and inadequate protection may lead to permanent injury due to diffuse necrosis, fibrosis, remodelling and long-term impairment of ventricular function. The need for longer periods of ischaemia in more metabolically vulnerable patients necessitates further research to improve protection strategies [</offsets><xref rid="EZU238C4" ref-type="bibr"><offsets xml_i="13349" xml_f="13350" txt_i="3459" txt_f="3460">4</offsets></xref><offsets xml_i="13357" xml_f="13359" txt_i="3460" txt_f="3462">].</offsets></p><p><offsets xml_i="13366" xml_f="13849" txt_i="3463" txt_f="3946">Pharmacological manipulation of myocardial metabolism aims to induce a shift in substrate utilization from fatty acids to glucose, thereby increasing energy efficiency and decreasing the potentially harmful effects of β-oxidation. Suppression of fatty acid utilization improves coupling of glycolysis to glucose oxidation, reduces lactate production, diminishes mitochondrial proton leakage and increases the efficiency of adenosine triphosphate (ATP) production per mole of oxygen [</offsets><xref rid="EZU238C5" ref-type="bibr"><offsets xml_i="13886" xml_f="13887" txt_i="3946" txt_f="3947">5</offsets></xref><offsets xml_i="13894" xml_f="14360" txt_i="3947" txt_f="4413">]. Metabolic drugs may have a role in myocardial protection as adjuncts to cardioplegia and hypothermia by increasing metabolic efficiency and reducing the impact of ischaemia–reperfusion injury, thereby translating into enhanced recovery of cardiac function during reperfusion, and improved clinical outcomes. We have previously shown that glucose–insulin–potassium (GIK) therapy improves myocardial protection in patients with multivessel disease undergoing CABG [</offsets><xref rid="EZU238C6" ref-type="bibr"><offsets xml_i="14397" xml_f="14398" txt_i="4413" txt_f="4414">6</offsets></xref><offsets xml_i="14405" xml_f="14491" txt_i="4414" txt_f="4500">] and in those with left ventricular hypertrophy undergoing aortic valve replacement [</offsets><xref rid="EZU238C7" ref-type="bibr"><offsets xml_i="14528" xml_f="14529" txt_i="4500" txt_f="4501">7</offsets></xref><offsets xml_i="14536" xml_f="15038" txt_i="4501" txt_f="5003">]. However, GIK therapy has not been widely adopted due to the lack of large multicentre randomized, controlled trials or a standardized protocol, increased monitoring requirements with high-dose insulin, the potential negative impact of perioperative hyperglycaemia and uncertainty over its mechanisms of action. An agent with a similar metabolic efficacy but without the complexity of administration is desirable although the evidence of benefit for such an agent in myocardial protection is lacking.</offsets></p><p><offsets xml_i="15045" xml_f="15184" txt_i="5004" txt_f="5143">Perhexiline is a modulator of myocardial metabolism that is effective in patients with refractory angina unsuitable for revascularization [</offsets><xref rid="EZU238C8" ref-type="bibr"><offsets xml_i="15221" xml_f="15222" txt_i="5143" txt_f="5144">8</offsets></xref><offsets xml_i="15229" xml_f="15260" txt_i="5144" txt_f="5175">] and chronic cardiac failure [</offsets><xref rid="EZU238C9" ref-type="bibr"><offsets xml_i="15297" xml_f="15298" txt_i="5175" txt_f="5176">9</offsets></xref><offsets xml_i="15305" xml_f="15307" txt_i="5176" txt_f="5178">, </offsets><xref rid="EZU238C10" ref-type="bibr"><offsets xml_i="15345" xml_f="15347" txt_i="5178" txt_f="5180">10</offsets></xref><offsets xml_i="15354" xml_f="15715" txt_i="5180" txt_f="5541">]. However, marked interindividual variation in its metabolism via cytochrome p450 2D6 (CYP2D6) previously resulted in severe adverse events due to chronic toxicity in a small number of poor metabolizers; toxicity can be prevented by therapeutic drug monitoring and dose adjustment to achieve plasma concentrations within the therapeutic range (0.15–0.6 mg/l) [</offsets><xref rid="EZU238C11" ref-type="bibr"><offsets xml_i="15753" xml_f="15755" txt_i="5541" txt_f="5543">11</offsets></xref><offsets xml_i="15762" xml_f="15981" txt_i="5543" txt_f="5762">]. In the rat heart, it has been shown to inhibit carnitine palmitoyltransferase-1 (CPT-1), the key uptake enzyme for long-chain fatty acids into mitochondria, and this is thought to be its primary mechanism of action [</offsets><xref rid="EZU238C12" ref-type="bibr"><offsets xml_i="16019" xml_f="16021" txt_i="5762" txt_f="5764">12</offsets></xref><offsets xml_i="16028" xml_f="16581" txt_i="5764" txt_f="6317">]. We report a prospective, double-blind, randomized, placebo-controlled trial to investigate whether preoperative administration of oral perhexiline improves clinical markers of myocardial protection in patients undergoing CABG at two centres in the UK. To examine the impact of perhexiline on myocardial metabolism in humans, we analysed the polar metabolic profile of left ventricular biopsies obtained prior to ischaemia from patients within the therapeutic range for perhexiline compared with controls using high-resolution mass spectrometry (MS) [</offsets><xref rid="EZU238C13" ref-type="bibr"><offsets xml_i="16619" xml_f="16621" txt_i="6317" txt_f="6319">13</offsets></xref><offsets xml_i="16628" xml_f="16766" txt_i="6319" txt_f="6457">]. The polar metabolome was chosen to provide the greatest insight into energy metabolism, including glycolysis and the citric acid cycle.</offsets></p></sec><sec sec-type="materials|methods" id="s2"><title><offsets xml_i="16825" xml_f="16846" txt_i="6459" txt_f="6480">MATERIALS AND METHODS</offsets></title><sec id="s2a"><title><offsets xml_i="16875" xml_f="16887" txt_i="6481" txt_f="6493">Study design</offsets></title><p><offsets xml_i="16898" xml_f="17810" txt_i="6494" txt_f="7406">A prospective, two-centre, double-blind, randomized, placebo-controlled trial of preoperative perhexiline (PEXSIG, Aspen Australia, Croydon, Victoria, Australia) was conducted in patients undergoing elective or urgent (during the same hospital admission) isolated, first-time CABG for multivessel coronary artery disease. The study was approved by the Cambridgeshire 1 Research Ethics Committee (06/Q0104/41) and the Medicines and Healthcare products Regulatory Agency (2006-003164-62). The trial was registered with ClinicalTrials.gov (NCT00845364), and patients were enrolled between February 2007 and April 2010 at the Queen Elizabeth Hospital Birmingham and the Royal Sussex County Hospital, Brighton, UK. Informed consent was obtained from each participant and all research was performed in accordance with the Declaration of Helsinki and the UK Human Tissue Act 2004 within a research governance framework.</offsets></p><p><offsets xml_i="17817" xml_f="18888" txt_i="7407" txt_f="8478">The exclusion criteria were diabetes mellitus, significant renal or hepatic impairment, peripheral neuropathy, porphyria, atrial fibrillation, recent amiodarone therapy, emergency surgery (before the next scheduled operating list), known hypersensitivity to perhexiline or prospectively identified as requiring a significant deviation from the protocol on clinical grounds. Patients were randomized to either perhexiline or placebo in a 1 : 1 ratio using a computer-generated random allocation sequence with minimization for surgeon, priority of surgery and left ventricular function. All tablets were identical in appearance to conceal allocation. Trial medication was commenced a minimum of 5 days prior to the planned date of surgery and continued for up to 31 days. A standardized loading and maintenance regime was used: 200 mg b.i.d. for 3 days followed by 100 mg b.i.d. until the morning of surgery. Blood was drawn prior to anaesthesia and stored; serum perhexiline concentrations were determined by high-performance liquid chromatography at the end of the trial.</offsets></p></sec><sec id="s2b"><title><offsets xml_i="18919" xml_f="18989" txt_i="8480" txt_f="8550">Surgery, anaesthesia, cardiopulmonary bypass and myocardial protection</offsets></title><p><offsets xml_i="19000" xml_f="19207" txt_i="8551" txt_f="8758">Anaesthesia, cardiopulmonary bypass (CPB) and myocardial protection with intermittent anterograde cardioplegia using St Thomas' solution buffered in cold blood were all standardized as previously described [</offsets><xref rid="EZU238C6" ref-type="bibr"><offsets xml_i="19244" xml_f="19245" txt_i="8758" txt_f="8759">6</offsets></xref><offsets xml_i="19252" xml_f="20241" txt_i="8759" txt_f="9748">], except that phenylepherine was used as the first-line vasoconstrictor. Distal anastomoses were performed during cardioplegic arrest and proximal anastomoses during partial aortic occlusion. A pulmonary artery catheter was used to assess haemodynamic variables, and the thermodilution technique was used to measure cardiac function. Baseline haemodynamic studies were performed prior to sternotomy. Following weaning from CPB, further measurements were taken before and ∼10 min after the administration of protamine, and then at 2, 4, 6, 9 and 12 h after release of the aortic cross-clamp. Standardized protocols were used to guide perioperative management including heart rate, volume expansion, inotrope use, temperature and glycaemic control. Serial blood samples were drawn at baseline at 6, 12 and 24 h to determine troponin-T by ECLIA (Roche Diagnostics, Burgess Hill, UK) and plasma non-esterified free fatty acids by enzymatic colorimetric assay (Wako Chemicals, Neuss, Germany).</offsets></p></sec><sec id="s2c"><title><offsets xml_i="20272" xml_f="20282" txt_i="9750" txt_f="9760">End-points</offsets></title><p><offsets xml_i="20293" xml_f="20418" txt_i="9761" txt_f="9883">The primary end-point was the incidence of a low cardiac output episode (LCOE), defined as a cardiac index of &lt;2.2 l/min/m</offsets><sup><offsets xml_i="20423" xml_f="20424" txt_i="9883" txt_f="9884">2</offsets></sup><offsets xml_i="20430" xml_f="20843" txt_i="9884" txt_f="10297"> refractory to appropriate intravascular volume expansion after correction of dysrhythmias in the first 6 h after cross-clamp release. A blinded end-points committee assessed all episodes of LCOE and a consensus opinion was reached. A planned exploratory analysis compared patients in the perhexiline arm who reached the lower threshold of the therapeutic range (0.15 mg/l) with propensity score-matched controls.</offsets></p><p><offsets xml_i="20850" xml_f="21329" txt_i="10298" txt_f="10777">Secondary end-points were a comparison of cardiac index and inotropic support in the first six and 12 h, peak and area under the concentration–time curve (AUC) for troponin-T in the first 24 h and perioperative myocardial injury on 12-lead electrocardiogram (ECG). ECG changes were assessed by an independent blinded cardiologist and defined as new Q waves ≥2 mm in two or more contiguous leads, new bundle branch block or loss of R wave progression by the 4th postoperative day.</offsets></p></sec><sec id="s2d"><title><offsets xml_i="21360" xml_f="21380" txt_i="10779" txt_f="10799">Metabolomic analysis</offsets></title><p><offsets xml_i="21391" xml_f="21690" txt_i="10800" txt_f="11099">Transmural biopsies of the left ventricular free wall between the left anterior descending artery and the first diagonal branch were obtained prior to application of the aortic cross-clamp and immediately snap-frozen. Metabolites were extracted using a methanol : water : chloroform solvent system [</offsets><xref rid="EZU238C14" ref-type="bibr"><offsets xml_i="21728" xml_f="21730" txt_i="11099" txt_f="11101">14</offsets></xref><offsets xml_i="21737" xml_f="22035" txt_i="11101" txt_f="11399">], dried using a centrifugal concentrator and stored at −80°C. Subsequently, each dried polar extract was re-dissolved in 80 : 20 methanol:water containing 20 mM ammonium acetate, vortexed and centrifuged prior to MS. Quality control (QC) samples were prepared by pooling an aliquot of each sample.</offsets></p><p><offsets xml_i="22042" xml_f="22349" txt_i="11400" txt_f="11707">MS analyses were conducted using a hybrid 7-Tesla linear ion trap Fourier transform ion cyclotron resonance (FT-ICR) MS (LTQ FT Ultra, Thermo Fisher Scientific, Germany) equipped with a Triversa chip-based nano-electrospray ion source (Advion Biosciences, NY, USA) using conditions as described previously [</offsets><xref rid="EZU238C15" ref-type="bibr"><offsets xml_i="22387" xml_f="22389" txt_i="11707" txt_f="11709">15</offsets></xref><offsets xml_i="22396" xml_f="22503" txt_i="11709" txt_f="11816">]. Three mass spectra for each sample were collected using a selected-ion-monitoring stitching method from </offsets><italic><offsets xml_i="22511" xml_f="22514" txt_i="11816" txt_f="11819">m/z</offsets></italic><offsets xml_i="22523" xml_f="22576" txt_i="11819" txt_f="11872"> (mass-to-charge ratio) 70–740 in negative ion mode [</offsets><xref rid="EZU238C15" ref-type="bibr"><offsets xml_i="22614" xml_f="22616" txt_i="11872" txt_f="11874">15</offsets></xref><offsets xml_i="22623" xml_f="22625" txt_i="11874" txt_f="11876">, </offsets><xref rid="EZU238C16" ref-type="bibr"><offsets xml_i="22663" xml_f="22665" txt_i="11876" txt_f="11878">16</offsets></xref><offsets xml_i="22672" xml_f="22753" txt_i="11878" txt_f="11959">], processed, normalized and generalized log-transformed as reported previously [</offsets><xref rid="EZU238C17" ref-type="bibr"><offsets xml_i="22791" xml_f="22793" txt_i="11959" txt_f="11961">17</offsets></xref><offsets xml_i="22800" xml_f="22802" txt_i="11961" txt_f="11963">, </offsets><xref rid="EZU238C18" ref-type="bibr"><offsets xml_i="22840" xml_f="22842" txt_i="11963" txt_f="11965">18</offsets></xref><offsets xml_i="22849" xml_f="22979" txt_i="11965" txt_f="12095">]. This produced a peak intensity matrix representing the metabolic profile of each extracted biopsy. Using the MI-Pack software [</offsets><xref rid="EZU238C19" ref-type="bibr"><offsets xml_i="23017" xml_f="23019" txt_i="12095" txt_f="12097">19</offsets></xref><offsets xml_i="23026" xml_f="23029" txt_i="12097" txt_f="12100">], </offsets><italic><offsets xml_i="23037" xml_f="23040" txt_i="12100" txt_f="12103">m/z</offsets></italic><offsets xml_i="23049" xml_f="23094" txt_i="12103" txt_f="12148"> measurements were putatively annotated (see </offsets><ext-link ext-link-type="uri" xlink:href="http://ejcts.oxfordjournals.org/lookup/suppl/doi:10.1093/ejcts/ezu238/-/DC1"><offsets xml_i="23213" xml_f="23235" txt_i="12148" txt_f="12170">Supplementary material</offsets></ext-link><offsets xml_i="23246" xml_f="23248" txt_i="12170" txt_f="12172">).</offsets></p></sec><sec id="s2e"><title><offsets xml_i="23279" xml_f="23299" txt_i="12174" txt_f="12194">Statistical analysis</offsets></title><sec id="s2e1"><title><offsets xml_i="23329" xml_f="23343" txt_i="12195" txt_f="12209">Clinical trial</offsets></title><p><offsets xml_i="23354" xml_f="23649" txt_i="12210" txt_f="12505">All analyses were prespecified and conducted according to the intention-to-treat principle. The trial had a statistical power of 90% to identify a relative risk of 0.50, which was statistically significant, assuming an incidence of LCOE in the control group of 0.37 and a conventional one-sided </offsets><italic><offsets xml_i="23657" xml_f="23658" txt_i="12505" txt_f="12506">α</offsets></italic><offsets xml_i="23667" xml_f="23880" txt_i="12506" txt_f="12719"> of 0.025. Analyses were conducted with SAS software version 9.1 or above (SAS Institute, Inc., Cary, NC, USA). Continuous data are presented as mean (standard deviation, SD) or median (interquartile range, IQR). </offsets><italic><offsets xml_i="23888" xml_f="23889" txt_i="12719" txt_f="12720">P</offsets></italic><offsets xml_i="23898" xml_f="24474" txt_i="12720" txt_f="13296">-values other than for the primary end-point were nominal. All analyses were stratified for left ventricular function and urgency of surgery as patient-level covariates, and surgeon as a random effect. Dichotomous outcomes were analysed with the use of nonlinear mixed models and continuous data with mixed models. Propensity scoring approaches were used to identify matched controls, based on age, race, weight, days of trial therapy, left ventricular function and priority of surgery. Supportive analyses were conducted using generalized linear models and repeated measures.</offsets></p></sec><sec id="s2e2"><title><offsets xml_i="24506" xml_f="24518" txt_i="13298" txt_f="13310">Metabolomics</offsets></title><p><offsets xml_i="24529" xml_f="24539" txt_i="13311" txt_f="13321">Student's </offsets><italic><offsets xml_i="24547" xml_f="24548" txt_i="13321" txt_f="13322">t</offsets></italic><offsets xml_i="24557" xml_f="24754" txt_i="13322" txt_f="13519">-tests were conducted on the non-generalized log-transformed peak intensity matrix, using a false discovery rate (FDR) of 5%, to determine if individual peaks changed significantly between groups [</offsets><xref rid="EZU238C20" ref-type="bibr"><offsets xml_i="24792" xml_f="24794" txt_i="13519" txt_f="13521">20</offsets></xref><offsets xml_i="24801" xml_f="25068" txt_i="13521" txt_f="13788">]. In addition, principal components analyses (PCA) and partial least squares-discriminant analyses (PLS-DA) were conducted to discover metabolic differences between groups. Internal cross-validation was applied to assess for over-fitting of the optimal PLS-DA model.</offsets></p><p><offsets xml_i="25075" xml_f="25109" txt_i="13789" txt_f="13823">Additional methods appears in the </offsets><ext-link ext-link-type="uri" xlink:href="http://ejcts.oxfordjournals.org/lookup/suppl/doi:10.1093/ejcts/ezu238/-/DC1"><offsets xml_i="25228" xml_f="25250" txt_i="13823" txt_f="13845">Supplementary material</offsets></ext-link><offsets xml_i="25261" xml_f="25262" txt_i="13845" txt_f="13846">.</offsets></p></sec></sec></sec><sec sec-type="results" id="s3"><title><offsets xml_i="25323" xml_f="25330" txt_i="13850" txt_f="13857">RESULTS</offsets></title><sec id="s3a"><title><offsets xml_i="25359" xml_f="25375" txt_i="13858" txt_f="13874">Study population</offsets></title><p><offsets xml_i="25386" xml_f="25490" txt_i="13875" txt_f="13979">Three hundred and twenty-seven patients were randomized of whom 286 were included in the analysis (Fig. </offsets><xref ref-type="fig" rid="EZU238F1"><offsets xml_i="25526" xml_f="25527" txt_i="13979" txt_f="13980">1</offsets></xref><offsets xml_i="25534" xml_f="25591" txt_i="13980" txt_f="14037">), 139 randomized to perhexiline and 147 to placebo (see </offsets><ext-link ext-link-type="uri" xlink:href="http://ejcts.oxfordjournals.org/lookup/suppl/doi:10.1093/ejcts/ezu238/-/DC1"><offsets xml_i="25710" xml_f="25732" txt_i="14037" txt_f="14059">Supplementary material</offsets></ext-link><offsets xml_i="25743" xml_f="25823" txt_i="14059" txt_f="14139">). Baseline preoperative characteristics were similar between the groups (Table </offsets><xref ref-type="table" rid="EZU238TB1"><offsets xml_i="25862" xml_f="25863" txt_i="14139" txt_f="14140">1</offsets></xref><offsets xml_i="25870" xml_f="26909" txt_i="14140" txt_f="15179">) including median logistic EuroSCORE: 1.82 (1.23–3.06) in the treatment arm and 1.82 (1.07–2.94) in the control arm. Participants took the trial medication for a median of 10 days (6–12 days) prior to surgery. Eighteen (6.3%) patients reported potential side effects of perhexiline, principally nausea or dizziness, of whom 15 were in the treatment group and three in the placebo group; 6 (4.3%) patients in the perhexiline group reported non-compliance with the dosing protocol due to side effects. Serum perhexiline at the time of surgery was measured in 280 patients including 135/139 (97.1%) in the treatment group in whom the median serum concentration was 0.24 mg/l (0.33 mg/l) with a range of 0.04–1.97 mg/l. In the perhexiline arm, 37 (27.4%) patients were below the lower threshold of the therapeutic range (0.15 mg/l); there was no correlation between serum perhexiline level and length of therapy. In the placebo group, all patients measured had a serum perhexiline level of zero, confirming the difference between the groups.
</offsets><table-wrap id="EZU238TB1" position="float"><label><offsets xml_i="26960" xml_f="26968" txt_i="15179" txt_f="15187">Table 1:</offsets></label><caption><p><offsets xml_i="26988" xml_f="27020" txt_i="15187" txt_f="15219">Baseline patient characteristics</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col></colgroup><thead><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="27303" xml_f="27316" txt_i="15220" txt_f="15233">Perhexiline (</offsets><italic><offsets xml_i="27324" xml_f="27325" txt_i="15233" txt_f="15234">n</offsets></italic><offsets xml_i="27334" xml_f="27341" txt_i="15234" txt_f="15241"> = 139)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="27387" xml_f="27396" txt_i="15241" txt_f="15250">Control (</offsets><italic><offsets xml_i="27404" xml_f="27405" txt_i="15250" txt_f="15251">n</offsets></italic><offsets xml_i="27414" xml_f="27421" txt_i="15251" txt_f="15258"> = 147)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="27478" xml_f="27503" txt_i="15258" txt_f="15283">Age, median (IQR) (years)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27536" xml_f="27552" txt_i="15284" txt_f="15300">66.1 (59.4–73.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27585" xml_f="27601" txt_i="15301" txt_f="15317">65.7 (60.2–73.6)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="27643" xml_f="27656" txt_i="15318" txt_f="15331">Male gender, </offsets><italic><offsets xml_i="27664" xml_f="27665" txt_i="15331" txt_f="15332">n</offsets></italic><offsets xml_i="27674" xml_f="27678" txt_i="15332" txt_f="15336"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27711" xml_f="27721" txt_i="15337" txt_f="15347">128 (92.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27754" xml_f="27764" txt_i="15348" txt_f="15358">134 (91.2)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="27806" xml_f="27812" txt_i="15359" txt_f="15365">Race, </offsets><italic><offsets xml_i="27820" xml_f="27821" txt_i="15365" txt_f="15366">n</offsets></italic><offsets xml_i="27830" xml_f="27834" txt_i="15366" txt_f="15370"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="27876" xml_f="27886" txt_i="15371" txt_f="15381"> Caucasian</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27919" xml_f="27929" txt_i="15382" txt_f="15392">133 (95.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="27962" xml_f="27972" txt_i="15393" txt_f="15403">136 (92.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28014" xml_f="28026" txt_i="15404" txt_f="15416"> South Asian</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28059" xml_f="28066" txt_i="15417" txt_f="15424">5 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28099" xml_f="28107" txt_i="15425" txt_f="15433">10 (6.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28149" xml_f="28155" txt_i="15434" txt_f="15440"> Black</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28188" xml_f="28195" txt_i="15441" txt_f="15448">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28228" xml_f="28235" txt_i="15449" txt_f="15456">1 (0.7)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="28277" xml_f="28288" txt_i="15457" txt_f="15468">CCS class, </offsets><italic><offsets xml_i="28296" xml_f="28297" txt_i="15468" txt_f="15469">n</offsets></italic><offsets xml_i="28306" xml_f="28310" txt_i="15469" txt_f="15473"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28352" xml_f="28354" txt_i="15474" txt_f="15476"> 0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28387" xml_f="28395" txt_i="15477" txt_f="15485">12 (8.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28428" xml_f="28435" txt_i="15486" txt_f="15493">7 (4.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28477" xml_f="28479" txt_i="15494" txt_f="15496"> I</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28512" xml_f="28519" txt_i="15497" txt_f="15504">9 (6.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28552" xml_f="28560" txt_i="15505" txt_f="15513">14 (9.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28602" xml_f="28605" txt_i="15514" txt_f="15517"> II</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28638" xml_f="28647" txt_i="15518" txt_f="15527">70 (50.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28680" xml_f="28689" txt_i="15528" txt_f="15537">71 (48.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28731" xml_f="28735" txt_i="15538" txt_f="15542"> III</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28768" xml_f="28777" txt_i="15543" txt_f="15552">39 (28.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28810" xml_f="28819" txt_i="15553" txt_f="15562">43 (29.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="28861" xml_f="28864" txt_i="15563" txt_f="15566"> IV</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28897" xml_f="28904" txt_i="15567" txt_f="15574">9 (6.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="28937" xml_f="28945" txt_i="15575" txt_f="15583">12 (8.2)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="28987" xml_f="28999" txt_i="15584" txt_f="15596">NYHA class, </offsets><italic><offsets xml_i="29007" xml_f="29008" txt_i="15596" txt_f="15597">n</offsets></italic><offsets xml_i="29017" xml_f="29021" txt_i="15597" txt_f="15601"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29063" xml_f="29065" txt_i="15602" txt_f="15604"> I</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29098" xml_f="29107" txt_i="15605" txt_f="15614">58 (41.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29140" xml_f="29149" txt_i="15615" txt_f="15624">59 (40.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29191" xml_f="29194" txt_i="15625" txt_f="15628"> II</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29227" xml_f="29236" txt_i="15629" txt_f="15638">68 (48.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29269" xml_f="29278" txt_i="15639" txt_f="15648">79 (53.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29320" xml_f="29324" txt_i="15649" txt_f="15653"> III</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29357" xml_f="29365" txt_i="15654" txt_f="15662">13 (9.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29398" xml_f="29405" txt_i="15663" txt_f="15670">9 (6.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29447" xml_f="29450" txt_i="15671" txt_f="15674"> IV</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29483" xml_f="29488" txt_i="15675" txt_f="15680">0 (0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29521" xml_f="29526" txt_i="15681" txt_f="15686">0 (0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29568" xml_f="29581" txt_i="15687" txt_f="15700">Previous MI, </offsets><italic><offsets xml_i="29589" xml_f="29590" txt_i="15700" txt_f="15701">n</offsets></italic><offsets xml_i="29599" xml_f="29603" txt_i="15701" txt_f="15705"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29636" xml_f="29645" txt_i="15706" txt_f="15715">49 (35.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29678" xml_f="29687" txt_i="15716" txt_f="15725">48 (32.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29729" xml_f="29754" txt_i="15726" txt_f="15751">Previous coronary stent, </offsets><italic><offsets xml_i="29762" xml_f="29763" txt_i="15751" txt_f="15752">n</offsets></italic><offsets xml_i="29772" xml_f="29776" txt_i="15752" txt_f="15756"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29809" xml_f="29817" txt_i="15757" txt_f="15765">13 (9.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29850" xml_f="29858" txt_i="15766" txt_f="15774">10 (6.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29900" xml_f="29929" txt_i="15775" txt_f="15804">Left main stem disease ≥50%, </offsets><italic><offsets xml_i="29937" xml_f="29938" txt_i="15804" txt_f="15805">n</offsets></italic><offsets xml_i="29947" xml_f="29951" txt_i="15805" txt_f="15809"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29984" xml_f="29993" txt_i="15810" txt_f="15819">54 (38.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30026" xml_f="30035" txt_i="15820" txt_f="15829">47 (32.0)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="30077" xml_f="30102" txt_i="15830" txt_f="15855">Left ventricle function, </offsets><italic><offsets xml_i="30110" xml_f="30111" txt_i="15855" txt_f="15856">n</offsets></italic><offsets xml_i="30120" xml_f="30124" txt_i="15856" txt_f="15860"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30166" xml_f="30171" txt_i="15861" txt_f="15866"> Good</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30204" xml_f="30214" txt_i="15867" txt_f="15877">118 (84.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30247" xml_f="30257" txt_i="15878" txt_f="15888">122 (83.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30299" xml_f="30308" txt_i="15889" txt_f="15898"> Moderate</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30341" xml_f="30350" txt_i="15899" txt_f="15908">20 (14.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30383" xml_f="30392" txt_i="15909" txt_f="15918">24 (16.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30434" xml_f="30439" txt_i="15919" txt_f="15924"> Poor</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30472" xml_f="30479" txt_i="15925" txt_f="15932">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30512" xml_f="30519" txt_i="15933" txt_f="15940">1 (0.7)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="30561" xml_f="30571" txt_i="15941" txt_f="15951">Priority, </offsets><italic><offsets xml_i="30579" xml_f="30580" txt_i="15951" txt_f="15952">n</offsets></italic><offsets xml_i="30589" xml_f="30593" txt_i="15952" txt_f="15956"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30635" xml_f="30644" txt_i="15957" txt_f="15966"> Elective</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30677" xml_f="30687" txt_i="15967" txt_f="15977">120 (86.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30720" xml_f="30730" txt_i="15978" txt_f="15988">124 (84.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30772" xml_f="30779" txt_i="15989" txt_f="15996"> Urgent</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30812" xml_f="30821" txt_i="15997" txt_f="16006">19 (13.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30854" xml_f="30863" txt_i="16007" txt_f="16016">23 (15.7)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="30905" xml_f="30913" txt_i="16017" txt_f="16025">Smoker, </offsets><italic><offsets xml_i="30921" xml_f="30922" txt_i="16025" txt_f="16026">n</offsets></italic><offsets xml_i="30931" xml_f="30935" txt_i="16026" txt_f="16030"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30977" xml_f="30981" txt_i="16031" txt_f="16035"> Non</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31014" xml_f="31023" txt_i="16036" txt_f="16045">38 (27.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31056" xml_f="31065" txt_i="16046" txt_f="16055">55 (37.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31107" xml_f="31115" txt_i="16056" txt_f="16064"> Current</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31148" xml_f="31157" txt_i="16065" txt_f="16074">14 (10.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31190" xml_f="31199" txt_i="16075" txt_f="16084">16 (10.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31241" xml_f="31251" txt_i="16085" txt_f="16095"> Ex-smoker</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31284" xml_f="31293" txt_i="16096" txt_f="16105">87 (62.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31326" xml_f="31335" txt_i="16106" txt_f="16115">76 (51.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31377" xml_f="31396" txt_i="16116" txt_f="16135">Pulmonary disease, </offsets><italic><offsets xml_i="31404" xml_f="31405" txt_i="16135" txt_f="16136">n</offsets></italic><offsets xml_i="31414" xml_f="31418" txt_i="16136" txt_f="16140"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31451" xml_f="31460" txt_i="16141" txt_f="16150">17 (12.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31493" xml_f="31501" txt_i="16151" txt_f="16159">12 (8.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31543" xml_f="31572" txt_i="16160" txt_f="16189">Peripheral vascular disease, </offsets><italic><offsets xml_i="31580" xml_f="31581" txt_i="16189" txt_f="16190">n</offsets></italic><offsets xml_i="31590" xml_f="31594" txt_i="16190" txt_f="16194"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31627" xml_f="31636" txt_i="16195" txt_f="16204">14 (10.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31669" xml_f="31677" txt_i="16205" txt_f="16213">10 (6.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31719" xml_f="31745" txt_i="16214" txt_f="16240">Recent MI (last 90 days), </offsets><italic><offsets xml_i="31753" xml_f="31754" txt_i="16240" txt_f="16241">n</offsets></italic><offsets xml_i="31763" xml_f="31767" txt_i="16241" txt_f="16245"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31800" xml_f="31809" txt_i="16246" txt_f="16255">19 (13.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31842" xml_f="31851" txt_i="16256" txt_f="16265">17 (11.6)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="31893" xml_f="31923" txt_i="16266" txt_f="16296">Number of antianginal agents, </offsets><italic><offsets xml_i="31931" xml_f="31932" txt_i="16296" txt_f="16297">n</offsets></italic><offsets xml_i="31941" xml_f="31945" txt_i="16297" txt_f="16301"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31987" xml_f="31989" txt_i="16302" txt_f="16304"> 0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32022" xml_f="32029" txt_i="16305" txt_f="16312">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32062" xml_f="32069" txt_i="16313" txt_f="16320">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32111" xml_f="32113" txt_i="16321" txt_f="16323"> 1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32146" xml_f="32155" txt_i="16324" txt_f="16333">68 (48.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32188" xml_f="32197" txt_i="16334" txt_f="16343">65 (44.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32239" xml_f="32241" txt_i="16344" txt_f="16346"> 2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32274" xml_f="32283" txt_i="16347" txt_f="16356">48 (34.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32316" xml_f="32325" txt_i="16357" txt_f="16366">55 (37.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32367" xml_f="32369" txt_i="16367" txt_f="16369"> 3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32402" xml_f="32411" txt_i="16370" txt_f="16379">15 (10.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32444" xml_f="32453" txt_i="16380" txt_f="16389">19 (12.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32495" xml_f="32497" txt_i="16390" txt_f="16392"> 4</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32530" xml_f="32537" txt_i="16393" txt_f="16400">5 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32570" xml_f="32577" txt_i="16401" txt_f="16408">6 (4.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32619" xml_f="32648" txt_i="16409" txt_f="16438">Haemoglobin, mean (SD) (g/dl)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32681" xml_f="32692" txt_i="16439" txt_f="16450">14.32 (1.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32725" xml_f="32736" txt_i="16451" txt_f="16462">14.11 (1.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32778" xml_f="32807" txt_i="16463" txt_f="16492">Creatinine, mean (SD) (mg/dl)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32840" xml_f="32850" txt_i="16493" txt_f="16503">1.20 (0.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32883" xml_f="32893" txt_i="16504" txt_f="16514">1.12 (0.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32935" xml_f="32958" txt_i="16515" txt_f="16538">EuroSCORE, median (IQR)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32991" xml_f="33001" txt_i="16539" txt_f="16549">3 (1 to 4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33034" xml_f="33044" txt_i="16550" txt_f="16560">3 (1 to 4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33086" xml_f="33118" txt_i="16561" txt_f="16593">Logistic EuroSCORE, median (IQR)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33151" xml_f="33170" txt_i="16594" txt_f="16613">1.82 (1.23 to 3.06)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33203" xml_f="33222" txt_i="16614" txt_f="16633">1.82 (1.07 to 2.94)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="TN1"><p><offsets xml_i="33281" xml_f="33429" txt_i="16634" txt_f="16782">CCS: Canadian Cardiovascular Society; NYHA: New York Heart Association; MI: myocardial infarction; SD: standard deviation; IQR: interquartile range.</offsets></p></fn></table-wrap-foot></table-wrap><offsets xml_i="33469" xml_f="33470" txt_i="16783" txt_f="16784">
</offsets><fig id="EZU238F1" position="float"><label><offsets xml_i="33513" xml_f="33522" txt_i="16784" txt_f="16793">Figure 1:</offsets></label><caption><p><offsets xml_i="33542" xml_f="33567" txt_i="16793" txt_f="16818">Participant flow diagram.</offsets></p></caption><graphic xlink:href="ezu23801"></graphic></fig></p><p><offsets xml_i="33635" xml_f="33952" txt_i="16820" txt_f="17137">All patients underwent multivessel CABG. One patient in the perhexiline and 3 in the control group had an additional mitral valve procedure and 1 further patient in the control group underwent aortic valve replacement. Operative variables including CPB and aortic cross-clamp times were similar between groups (Table </offsets><xref ref-type="table" rid="EZU238TB2"><offsets xml_i="33991" xml_f="33992" txt_i="17137" txt_f="17138">2</offsets></xref><offsets xml_i="33999" xml_f="34002" txt_i="17138" txt_f="17141">).
</offsets><table-wrap id="EZU238TB2" position="float"><label><offsets xml_i="34053" xml_f="34061" txt_i="17141" txt_f="17149">Table 2:</offsets></label><caption><p><offsets xml_i="34081" xml_f="34100" txt_i="17149" txt_f="17168">Operative variables</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col></colgroup><thead><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="34383" xml_f="34396" txt_i="17169" txt_f="17182">Perhexiline (</offsets><italic><offsets xml_i="34404" xml_f="34405" txt_i="17182" txt_f="17183">n</offsets></italic><offsets xml_i="34414" xml_f="34421" txt_i="17183" txt_f="17190"> = 139)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="34467" xml_f="34476" txt_i="17190" txt_f="17199">Control (</offsets><italic><offsets xml_i="34484" xml_f="34485" txt_i="17199" txt_f="17200">n</offsets></italic><offsets xml_i="34494" xml_f="34501" txt_i="17200" txt_f="17207"> = 147)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="34558" xml_f="34585" txt_i="17207" txt_f="17234">Number of grafts, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34618" xml_f="34629" txt_i="17235" txt_f="17246">3.30 (0.73)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34662" xml_f="34673" txt_i="17247" txt_f="17258">3.29 (0.82)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34715" xml_f="34751" txt_i="17259" txt_f="17295">Internal mammary artery graft used, </offsets><italic><offsets xml_i="34759" xml_f="34760" txt_i="17295" txt_f="17296">n</offsets></italic><offsets xml_i="34769" xml_f="34773" txt_i="17296" txt_f="17300"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34806" xml_f="34816" txt_i="17301" txt_f="17311">132 (95.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34849" xml_f="34859" txt_i="17312" txt_f="17322">136 (92.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34901" xml_f="34923" txt_i="17323" txt_f="17345">Additional procedure, </offsets><italic><offsets xml_i="34931" xml_f="34932" txt_i="17345" txt_f="17346">n</offsets></italic><offsets xml_i="34941" xml_f="34945" txt_i="17346" txt_f="17350"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34978" xml_f="34985" txt_i="17351" txt_f="17358">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35018" xml_f="35025" txt_i="17359" txt_f="17366">4 (2.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35067" xml_f="35099" txt_i="17367" txt_f="17399">Operation performed by trainee, </offsets><italic><offsets xml_i="35107" xml_f="35108" txt_i="17399" txt_f="17400">n</offsets></italic><offsets xml_i="35117" xml_f="35121" txt_i="17400" txt_f="17404"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35154" xml_f="35163" txt_i="17405" txt_f="17414">38 (27.3)</offsets><sup><offsets xml_i="35168" xml_f="35169" txt_i="17414" txt_f="17415">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="35208" xml_f="35217" txt_i="17416" txt_f="17425">50 (34.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35259" xml_f="35287" txt_i="17426" txt_f="17454">CPB time, median (IQR) (min)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35320" xml_f="35332" txt_i="17455" txt_f="17467">109 (93–131)</offsets><sup><offsets xml_i="35337" xml_f="35338" txt_i="17467" txt_f="17468">b</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="35377" xml_f="35389" txt_i="17469" txt_f="17481">110 (90–134)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35431" xml_f="35453" txt_i="17482" txt_f="17504">Reinstitution of CPB, </offsets><italic><offsets xml_i="35461" xml_f="35462" txt_i="17504" txt_f="17505">n</offsets></italic><offsets xml_i="35471" xml_f="35475" txt_i="17505" txt_f="17509"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35508" xml_f="35515" txt_i="17510" txt_f="17517">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35548" xml_f="35555" txt_i="17518" txt_f="17525">6 (4.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35597" xml_f="35640" txt_i="17526" txt_f="17569">Aortic cross-clamp time, median (IQR) (min)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35673" xml_f="35683" txt_i="17570" txt_f="17580">56 (45–70)</offsets><sup><offsets xml_i="35688" xml_f="35689" txt_i="17580" txt_f="17581">b</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="35728" xml_f="35738" txt_i="17582" txt_f="17592">57 (45–72)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35780" xml_f="35821" txt_i="17593" txt_f="17634">Total cardioplegia dose, median (IQR) (l)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35854" xml_f="35870" txt_i="17635" txt_f="17651">1.95 (1.70–2.30)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35903" xml_f="35919" txt_i="17652" txt_f="17668">1.90 (1.62–2.24)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35961" xml_f="35980" txt_i="17669" txt_f="17688">Reperfusion VF/VT, </offsets><italic><offsets xml_i="35988" xml_f="35989" txt_i="17688" txt_f="17689">n</offsets></italic><offsets xml_i="35998" xml_f="36002" txt_i="17689" txt_f="17693"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36035" xml_f="36042" txt_i="17694" txt_f="17701">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36075" xml_f="36082" txt_i="17702" txt_f="17709">3 (2.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36124" xml_f="36147" txt_i="17710" txt_f="17733">Antifibrinolytic used, </offsets><italic><offsets xml_i="36155" xml_f="36156" txt_i="17733" txt_f="17734">n</offsets></italic><offsets xml_i="36165" xml_f="36169" txt_i="17734" txt_f="17738"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36202" xml_f="36211" txt_i="17739" txt_f="17748">97 (69.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36244" xml_f="36254" txt_i="17749" txt_f="17759">100 (68.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36296" xml_f="36334" txt_i="17760" txt_f="17798">Cell salvaged blood, median (IQR) (ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36367" xml_f="36380" txt_i="17799" txt_f="17812">470 (260–700)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36413" xml_f="36426" txt_i="17813" txt_f="17826">485 (300–700)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36468" xml_f="36500" txt_i="17827" txt_f="17859">Intra-aortic balloon pump used, </offsets><italic><offsets xml_i="36508" xml_f="36509" txt_i="17859" txt_f="17860">n</offsets></italic><offsets xml_i="36518" xml_f="36522" txt_i="17860" txt_f="17864"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36555" xml_f="36563" txt_i="17865" txt_f="17873">10 (7.2)</offsets><sup><offsets xml_i="36568" xml_f="36569" txt_i="17873" txt_f="17874">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="36608" xml_f="36617" txt_i="17875" txt_f="17884">21 (14.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36659" xml_f="36685" txt_i="17885" txt_f="17911"> Preop for unstable angina</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36718" xml_f="36725" txt_i="17912" txt_f="17919">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36758" xml_f="36763" txt_i="17920" txt_f="17925">0 (0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36805" xml_f="36831" txt_i="17926" txt_f="17952"> Preop elective in theatre</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36864" xml_f="36871" txt_i="17953" txt_f="17960">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36904" xml_f="36911" txt_i="17961" txt_f="17968">6 (4.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36953" xml_f="36992" txt_i="17969" txt_f="18008"> Pre-CPB for intraoperative instability</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37025" xml_f="37032" txt_i="18009" txt_f="18016">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37065" xml_f="37070" txt_i="18017" txt_f="18022">0 (0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37112" xml_f="37151" txt_i="18023" txt_f="18062"> During CPB for anticipated instability</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37184" xml_f="37191" txt_i="18063" txt_f="18070">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37224" xml_f="37231" txt_i="18071" txt_f="18078">4 (2.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37273" xml_f="37298" txt_i="18079" txt_f="18104"> Post-CPB for instability</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37331" xml_f="37338" txt_i="18105" txt_f="18112">3 (2.2)</offsets><sup><offsets xml_i="37343" xml_f="37344" txt_i="18112" txt_f="18113">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="37383" xml_f="37391" txt_i="18114" txt_f="18122">11 (7.6)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="TN2"><p><offsets xml_i="37450" xml_f="37592" txt_i="18123" txt_f="18265">Reinstitution of CPB relates to episodes of unsuccessful weaning from CPB requiring a second period of CPB to prevent cardiovascular collapse.</offsets></p></fn><fn id="TN3"><p><offsets xml_i="37617" xml_f="37754" txt_i="18266" txt_f="18403">CPB: cardiopulmonary bypass; VF: ventricular fibrillation; VT: ventricular tachycardia; SD: standard deviation; IQR: interquartile range.</offsets></p></fn><fn id="TN4"><p><sup><offsets xml_i="37784" xml_f="37785" txt_i="18404" txt_f="18405">a</offsets></sup><offsets xml_i="37791" xml_f="37832" txt_i="18405" txt_f="18446">Not significant with Fisher's exact test.</offsets></p></fn><fn id="TN5"><p><sup><offsets xml_i="37862" xml_f="37863" txt_i="18447" txt_f="18448">b</offsets></sup><offsets xml_i="37869" xml_f="37900" txt_i="18448" txt_f="18479">Not significant with Student's </offsets><italic><offsets xml_i="37908" xml_f="37909" txt_i="18479" txt_f="18480">t</offsets></italic><offsets xml_i="37918" xml_f="37924" txt_i="18480" txt_f="18486">-test.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3b"><title><offsets xml_i="37995" xml_f="38010" txt_i="18489" txt_f="18504">Primary outcome</offsets></title><p><offsets xml_i="38021" xml_f="38269" txt_i="18505" txt_f="18753">A LCOE was diagnosed in 102 of 286 (35.7%) patients analysed; however, there was no significant difference in incidence between the two groups: 51/139 (36.7%) in the perhexiline arm and 51/147 (34.7%) in the control arm (OR 0.92, 95% CI 0.56–1.50, </offsets><italic><offsets xml_i="38277" xml_f="38278" txt_i="18753" txt_f="18754">P</offsets></italic><offsets xml_i="38287" xml_f="38303" txt_i="18754" txt_f="18770"> = 0.74) (Table </offsets><xref ref-type="table" rid="EZU238TB3"><offsets xml_i="38342" xml_f="38343" txt_i="18770" txt_f="18771">3</offsets></xref><offsets xml_i="38350" xml_f="38564" txt_i="18771" txt_f="18985">). In the exploratory analysis, patients in the perhexiline arm who were above the lower threshold of the therapeutic range (≥0.15 mg/l) at the time of surgery were compared with propensity score-matched controls (</offsets><italic><offsets xml_i="38572" xml_f="38573" txt_i="18985" txt_f="18986">n</offsets></italic><offsets xml_i="38582" xml_f="38815" txt_i="18986" txt_f="19219"> = 97 in each group, 1 patient excluded due to missing data). There remained no significant difference in the incidence of LCOE between groups: 38/97 (39.2%) for perhexiline and 31/97 (32.0%) for controls (OR 0.73, 95% CI 0.40–1.33, </offsets><italic><offsets xml_i="38823" xml_f="38824" txt_i="19219" txt_f="19220">P</offsets></italic><offsets xml_i="38833" xml_f="38843" txt_i="19220" txt_f="19230"> = 0.30).
</offsets><table-wrap id="EZU238TB3" position="float"><label><offsets xml_i="38894" xml_f="38902" txt_i="19230" txt_f="19238">Table 3:</offsets></label><caption><p><offsets xml_i="38922" xml_f="38991" txt_i="19238" txt_f="19307">Study outcomes, the perhexiline group compared with the control group</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="39289" xml_f="39297" txt_i="19308" txt_f="19316">Outcomes</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="39343" xml_f="39354" txt_i="19316" txt_f="19327">Perhexiline</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="39400" xml_f="39407" txt_i="19327" txt_f="19334">Control</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="39453" xml_f="39472" txt_i="19334" txt_f="19353">Odds ratio (95% CI)</offsets></th><th align="left" rowspan="1" colspan="1"><italic><offsets xml_i="39526" xml_f="39527" txt_i="19353" txt_f="19354">P</offsets></italic><offsets xml_i="39536" xml_f="39542" txt_i="19354" txt_f="19360">-value</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="39599" xml_f="39616" txt_i="19360" txt_f="19377">Primary outcome, </offsets><italic><offsets xml_i="39624" xml_f="39625" txt_i="19377" txt_f="19378">n</offsets></italic><offsets xml_i="39634" xml_f="39638" txt_i="19378" txt_f="19382"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39671" xml_f="39674" txt_i="19383" txt_f="19386">139</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39707" xml_f="39710" txt_i="19387" txt_f="19390">147</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39818" xml_f="39845" txt_i="19393" txt_f="19420"> Low cardiac output episode</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39878" xml_f="39889" txt_i="19421" txt_f="19432">51 (36.69%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39922" xml_f="39933" txt_i="19433" txt_f="19444">51 (34.69%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39966" xml_f="39985" txt_i="19445" txt_f="19464">0.92 (0.56 to 1.50)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40018" xml_f="40022" txt_i="19465" txt_f="19469">0.74</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40064" xml_f="40097" txt_i="19470" txt_f="19503">Secondary outcomes, categorical, </offsets><italic><offsets xml_i="40105" xml_f="40106" txt_i="19503" txt_f="19504">n</offsets></italic><offsets xml_i="40115" xml_f="40119" txt_i="19504" txt_f="19508"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40152" xml_f="40155" txt_i="19509" txt_f="19512">139</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40188" xml_f="40191" txt_i="19513" txt_f="19516">147</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40299" xml_f="40325" txt_i="19519" txt_f="19545"> Inotrope use in first 6 h</offsets><sup><offsets xml_i="40330" xml_f="40331" txt_i="19545" txt_f="19546">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="40370" xml_f="40381" txt_i="19547" txt_f="19558">39 (28.06%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40414" xml_f="40425" txt_i="19559" txt_f="19570">36 (24.49%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40458" xml_f="40477" txt_i="19571" txt_f="19590">0.84 (0.49 to 1.44)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40510" xml_f="40514" txt_i="19591" txt_f="19595">0.52</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40556" xml_f="40583" txt_i="19596" txt_f="19623"> Inotrope use in first 12 h</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40616" xml_f="40627" txt_i="19624" txt_f="19635">67 (48.20%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40660" xml_f="40671" txt_i="19636" txt_f="19647">50 (34.01%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40704" xml_f="40723" txt_i="19648" txt_f="19667">0.55 (0.34 to 0.89)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40756" xml_f="40761" txt_i="19668" txt_f="19673">0.015</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="40803" xml_f="40832" txt_i="19674" txt_f="19703"> New myocardial injury on ECG</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40865" xml_f="40876" txt_i="19704" txt_f="19715">23 (16.55%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40909" xml_f="40920" txt_i="19716" txt_f="19727">25 (17.01%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40953" xml_f="40972" txt_i="19728" txt_f="19747">1.02 (0.55 to 1.92)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41005" xml_f="41009" txt_i="19748" txt_f="19752">0.94</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41051" xml_f="41092" txt_i="19753" txt_f="19794">Secondary outcomes, continuous, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41125" xml_f="41128" txt_i="19795" txt_f="19798">135</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41161" xml_f="41164" txt_i="19799" txt_f="19802">144</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41272" xml_f="41302" txt_i="19805" txt_f="19835"> Cardiac index at 6 h (l/min/m</offsets><sup><offsets xml_i="41307" xml_f="41308" txt_i="19835" txt_f="19836">2</offsets></sup><offsets xml_i="41314" xml_f="41315" txt_i="19836" txt_f="19837">)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41348" xml_f="41359" txt_i="19838" txt_f="19849">2.51 (0.43)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41392" xml_f="41403" txt_i="19850" txt_f="19861">2.70 (0.54)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41436" xml_f="41455" txt_i="19862" txt_f="19881">0.19 (0.07 to 0.31)</offsets><sup><offsets xml_i="41460" xml_f="41461" txt_i="19881" txt_f="19882">b</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="41500" xml_f="41505" txt_i="19883" txt_f="19888">0.001</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41547" xml_f="41571" txt_i="19889" txt_f="19913"> Peak troponin-T (ng/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41604" xml_f="41615" txt_i="19914" txt_f="19925">0.78 (0.71)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41648" xml_f="41659" txt_i="19926" txt_f="19937">0.89 (0.92)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41692" xml_f="41712" txt_i="19938" txt_f="19958">0.11 (−0.09 to 0.30)</offsets><sup><offsets xml_i="41717" xml_f="41718" txt_i="19958" txt_f="19959">b</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="41757" xml_f="41761" txt_i="19960" txt_f="19964">0.28</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="41803" xml_f="41828" txt_i="19965" txt_f="19990"> AUC troponin-T (ng h/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41861" xml_f="41872" txt_i="19991" txt_f="20002">3.98 (3.79)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41905" xml_f="41916" txt_i="20003" txt_f="20014">4.71 (5.32)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="41949" xml_f="41969" txt_i="20015" txt_f="20035">0.73 (−0.40 to 1.86)</offsets><sup><offsets xml_i="41974" xml_f="41975" txt_i="20035" txt_f="20036">b</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="42014" xml_f="42018" txt_i="20037" txt_f="20041">0.12</offsets><sup><offsets xml_i="42023" xml_f="42024" txt_i="20041" txt_f="20042">c</offsets></sup></td></tr></tbody></table><table-wrap-foot><fn id="TN6"><p><offsets xml_i="42089" xml_f="42196" txt_i="20043" txt_f="20150">Accounting for baseline left ventricular function and priority of surgery, with surgeon as a random effect.</offsets></p></fn><fn id="TN7"><p><offsets xml_i="42221" xml_f="42290" txt_i="20151" txt_f="20220">SD: standard deviation; AUC: area under the concentration-time curve.</offsets></p></fn><fn id="TN8"><p><sup><offsets xml_i="42320" xml_f="42321" txt_i="20221" txt_f="20222">a</offsets></sup><offsets xml_i="42327" xml_f="42398" txt_i="20222" txt_f="20293">Before cardiopulmonary bypass, during cardiopulmonary bypass and 0–6 h.</offsets></p></fn><fn id="TN9"><p><sup><offsets xml_i="42428" xml_f="42429" txt_i="20294" txt_f="20295">b</offsets></sup><offsets xml_i="42435" xml_f="42481" txt_i="20295" txt_f="20341">Difference in means (95% confidence interval).</offsets></p></fn><fn id="TN10"><p><sup><offsets xml_i="42512" xml_f="42513" txt_i="20342" txt_f="20343">c</offsets></sup><offsets xml_i="42519" xml_f="42530" txt_i="20343" txt_f="20354">One-tailed.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3c"><title><offsets xml_i="42601" xml_f="42619" txt_i="20357" txt_f="20375">Secondary outcomes</offsets></title><sec id="s3c1"><title><offsets xml_i="42649" xml_f="42666" txt_i="20376" txt_f="20393">Haemodynamic data</offsets></title><p><offsets xml_i="42677" xml_f="42792" txt_i="20394" txt_f="20509">At 6 h following reperfusion, the mean cardiac index was significantly lower in the perhexiline group (2.51 l/min/m</offsets><sup><offsets xml_i="42797" xml_f="42798" txt_i="20509" txt_f="20510">2</offsets></sup><offsets xml_i="42804" xml_f="42854" txt_i="20510" txt_f="20560">, SD 0.43) than in the control group (2.70 l/min/m</offsets><sup><offsets xml_i="42859" xml_f="42860" txt_i="20560" txt_f="20561">2</offsets></sup><offsets xml_i="42866" xml_f="42922" txt_i="20561" txt_f="20617">, SD 0.54) (difference in means 0.19, 95% CI 0.07–0.31, </offsets><italic><offsets xml_i="42930" xml_f="42931" txt_i="20617" txt_f="20618">P</offsets></italic><offsets xml_i="42940" xml_f="42956" txt_i="20618" txt_f="20634"> = 0.001) (Fig. </offsets><xref ref-type="fig" rid="EZU238F2"><offsets xml_i="42992" xml_f="42993" txt_i="20634" txt_f="20635">2</offsets></xref><offsets xml_i="43000" xml_f="43086" txt_i="20635" txt_f="20721">). By 12 h after reperfusion, there was no difference between the groups: 2.73 l/min/m</offsets><sup><offsets xml_i="43091" xml_f="43092" txt_i="20721" txt_f="20722">2</offsets></sup><offsets xml_i="43098" xml_f="43140" txt_i="20722" txt_f="20764"> (SD 0.54) for perhexiline vs 2.79 l/min/m</offsets><sup><offsets xml_i="43145" xml_f="43146" txt_i="20764" txt_f="20765">2</offsets></sup><offsets xml_i="43152" xml_f="43223" txt_i="20765" txt_f="20836"> (SD 0.48) for controls (difference in means 0.058, 95% CI −0.06–0.18, </offsets><italic><offsets xml_i="43231" xml_f="43232" txt_i="20836" txt_f="20837">P</offsets></italic><offsets xml_i="43241" xml_f="43398" txt_i="20837" txt_f="20994"> = 0.34). Throughout the study, heart rate, mean arterial pressure, central venous pressure and pulmonary artery wedge pressure were similar between groups.
</offsets><fig id="EZU238F2" position="float"><label><offsets xml_i="43441" xml_f="43450" txt_i="20994" txt_f="21003">Figure 2:</offsets></label><caption><p><offsets xml_i="43470" xml_f="43497" txt_i="21003" txt_f="21030">Mean cardiac index (l/min/m</offsets><sup><offsets xml_i="43502" xml_f="43503" txt_i="21030" txt_f="21031">2</offsets></sup><offsets xml_i="43509" xml_f="43602" txt_i="21031" txt_f="21124">) between treatment groups. Error bars represent 95% confidence intervals (CI) for the mean (</offsets><italic><offsets xml_i="43610" xml_f="43611" txt_i="21124" txt_f="21125">P</offsets></italic><offsets xml_i="43620" xml_f="43637" txt_i="21125" txt_f="21142"> = 0.018 at 6 h).</offsets></p></caption><graphic xlink:href="ezu23802"></graphic></fig></p><p><offsets xml_i="43705" xml_f="43821" txt_i="21144" txt_f="21260">Cardiac index measured prior to ischaemia was found to be significantly lower in the perhexiline group (2.09 l/min/m</offsets><sup><offsets xml_i="43826" xml_f="43827" txt_i="21260" txt_f="21261">2</offsets></sup><offsets xml_i="43833" xml_f="43883" txt_i="21261" txt_f="21311">, SD 0.57) than in the control group (2.31 l/min/m</offsets><sup><offsets xml_i="43888" xml_f="43889" txt_i="21311" txt_f="21312">2</offsets></sup><offsets xml_i="43895" xml_f="43951" txt_i="21312" txt_f="21368">, SD 0.53) (difference in means 0.22, 95% CI 0.09–0.35, </offsets><italic><offsets xml_i="43959" xml_f="43960" txt_i="21368" txt_f="21369">P</offsets></italic><offsets xml_i="43969" xml_f="44130" txt_i="21369" txt_f="21530"> = 0.001). Using repeated measures, the cardiac index was found to be significantly affected by perhexiline therapy (difference in means 0.13, 95% CI 0.08–0.17, </offsets><italic><offsets xml_i="44138" xml_f="44139" txt_i="21530" txt_f="21531">P</offsets></italic><offsets xml_i="44148" xml_f="44161" txt_i="21531" txt_f="21541"> &lt; .0001).</offsets></p></sec><sec id="s3c2"><title><offsets xml_i="44193" xml_f="44225" txt_i="21543" txt_f="21575">Inotrope and vasoconstrictor use</offsets></title><p><offsets xml_i="44236" xml_f="44416" txt_i="21576" txt_f="21756">There was no difference in the prevalence of inotropic support in the first 6 h after reperfusion: perhexiline 39/139 (28.1%) vs control 36/147 (24.5%) (OR 0.84, 95% CI 0.49–1.44, </offsets><italic><offsets xml_i="44424" xml_f="44425" txt_i="21756" txt_f="21757">P</offsets></italic><offsets xml_i="44434" xml_f="44617" txt_i="21757" txt_f="21940"> = 0.52). However, by 12 h, inotrope use was significantly more frequent in the perhexiline group (67/139, 48.2%) versus the control group (50/147, 34.0%) (OR 0.55, 95% CI 0.34–0.89, </offsets><italic><offsets xml_i="44625" xml_f="44626" txt_i="21940" txt_f="21941">P</offsets></italic><offsets xml_i="44635" xml_f="44732" txt_i="21941" txt_f="22038"> = 0.015). There were no differences between groups in the dose requirements for phenylepherine (</offsets><italic><offsets xml_i="44740" xml_f="44741" txt_i="22038" txt_f="22039">P</offsets></italic><offsets xml_i="44750" xml_f="44776" txt_i="22039" txt_f="22065"> = 0.26), norepinephrine (</offsets><italic><offsets xml_i="44784" xml_f="44785" txt_i="22065" txt_f="22066">P</offsets></italic><offsets xml_i="44794" xml_f="44815" txt_i="22066" txt_f="22087"> = 0.12) or insulin (</offsets><italic><offsets xml_i="44823" xml_f="44824" txt_i="22087" txt_f="22088">P</offsets></italic><offsets xml_i="44833" xml_f="44860" txt_i="22088" txt_f="22115"> = 0.43) in the first 12 h.</offsets></p></sec><sec id="s3c3"><title><offsets xml_i="44892" xml_f="44909" txt_i="22117" txt_f="22134">Myocardial injury</offsets></title><p><offsets xml_i="44920" xml_f="45164" txt_i="22135" txt_f="22379">There was no difference in the mean peak serum troponin-T concentration during the first 24 h after surgery: 0.78 ng/ml (SD 0.71) in perhexiline patients vs 0.89 ng/ml (SD 0.92) in control patients (difference in means 0.11, 95% CI −0.09–0.30, </offsets><italic><offsets xml_i="45172" xml_f="45173" txt_i="22379" txt_f="22380">P</offsets></italic><offsets xml_i="45182" xml_f="45341" txt_i="22380" txt_f="22539"> = 0.28). The AUC in the first 24 h was also not significantly different between groups: perhexiline 3.98 ng h/ml (SD 3.79) vs control 4.71 ng h/ml (SD 5.32) (</offsets><italic><offsets xml_i="45349" xml_f="45350" txt_i="22539" txt_f="22540">P</offsets></italic><offsets xml_i="45359" xml_f="45374" txt_i="22540" txt_f="22555"> = 0.12) (Fig. </offsets><xref ref-type="fig" rid="EZU238F3"><offsets xml_i="45410" xml_f="45411" txt_i="22555" txt_f="22556">3</offsets></xref><offsets xml_i="45418" xml_f="45623" txt_i="22556" txt_f="22761">). There was no difference in the frequency of ECG changes consistent with new myocardial injury: 23/139 (16.6%) in the perhexiline group vs 25/147 (17.0%) in the control group (OR 1.02, 95% CI 0.55–1.92, </offsets><italic><offsets xml_i="45631" xml_f="45632" txt_i="22761" txt_f="22762">P</offsets></italic><offsets xml_i="45641" xml_f="45651" txt_i="22762" txt_f="22772"> = 0.94).
</offsets><fig id="EZU238F3" position="float"><label><offsets xml_i="45694" xml_f="45703" txt_i="22772" txt_f="22781">Figure 3:</offsets></label><caption><p><offsets xml_i="45723" xml_f="45795" txt_i="22781" txt_f="22853">Area under the concentration–time curve for serum troponin-T (ng h/ml) (</offsets><italic><offsets xml_i="45803" xml_f="45804" txt_i="22853" txt_f="22854">P</offsets></italic><offsets xml_i="45813" xml_f="45822" txt_i="22854" txt_f="22863"> = 0.12).</offsets></p></caption><graphic xlink:href="ezu23803"></graphic></fig></p><p><offsets xml_i="45890" xml_f="45971" txt_i="22865" txt_f="22946">Plasma non-esterified free fatty acids were measured in 35 patients (perhexiline </offsets><italic><offsets xml_i="45979" xml_f="45980" txt_i="22946" txt_f="22947">n</offsets></italic><offsets xml_i="45989" xml_f="46004" txt_i="22947" txt_f="22962"> = 16, control </offsets><italic><offsets xml_i="46012" xml_f="46013" txt_i="22962" txt_f="22963">n</offsets></italic><offsets xml_i="46022" xml_f="46183" txt_i="22963" txt_f="23124"> = 19) and found to be significantly higher prior to ischaemia in the perhexiline group (0.75 mmol/l, SD 0.08) than in the control group (0.50 mmol/l, SD 0.13) (</offsets><italic><offsets xml_i="46191" xml_f="46192" txt_i="23124" txt_f="23125">P</offsets></italic><offsets xml_i="46201" xml_f="46359" txt_i="23125" txt_f="23280"> &lt; 0.001). This difference was lost by 6 h into reperfusion: 0.73 mmol/l (SD 0.15) in the perhexiline group vs 0.70 mmol/l (SD 0.21) in the control group (</offsets><italic><offsets xml_i="46367" xml_f="46368" txt_i="23280" txt_f="23281">P</offsets></italic><offsets xml_i="46377" xml_f="46520" txt_i="23281" txt_f="23424"> = 0.64). No significant relationship between plasma free fatty acid concentration and pre-ischaemic cardiac index was observed on regression (</offsets><italic><offsets xml_i="46528" xml_f="46529" txt_i="23424" txt_f="23425">R</offsets><sup><offsets xml_i="46534" xml_f="46535" txt_i="23425" txt_f="23426">2</offsets></sup></italic><offsets xml_i="46550" xml_f="46559" txt_i="23426" txt_f="23435"> = 0.09, </offsets><italic><offsets xml_i="46567" xml_f="46568" txt_i="23435" txt_f="23436">P</offsets></italic><offsets xml_i="46577" xml_f="46586" txt_i="23436" txt_f="23445"> = 0.08).</offsets></p><p><offsets xml_i="46593" xml_f="46795" txt_i="23446" txt_f="23648">There were no significant differences in the prespecified safety end-points of death, stroke, the need for renal replacement therapy, reoperation or length of ICU or hospital stay between groups (Table </offsets><xref ref-type="table" rid="EZU238TB4"><offsets xml_i="46834" xml_f="46835" txt_i="23648" txt_f="23649">4</offsets></xref><offsets xml_i="46842" xml_f="46845" txt_i="23649" txt_f="23652">).
</offsets><table-wrap id="EZU238TB4" position="float"><label><offsets xml_i="46896" xml_f="46904" txt_i="23652" txt_f="23660">Table 4:</offsets></label><caption><p><offsets xml_i="46924" xml_f="46965" txt_i="23660" txt_f="23701">Other clinical outcomes and complications</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="char" char="(" span="1"></col><col align="char" char="(" span="1"></col></colgroup><thead><tr><th rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47248" xml_f="47261" txt_i="23702" txt_f="23715">Perhexiline (</offsets><italic><offsets xml_i="47269" xml_f="47270" txt_i="23715" txt_f="23716">n</offsets></italic><offsets xml_i="47279" xml_f="47286" txt_i="23716" txt_f="23723"> = 139)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="47332" xml_f="47341" txt_i="23723" txt_f="23732">Control (</offsets><italic><offsets xml_i="47349" xml_f="47350" txt_i="23732" txt_f="23733">n</offsets></italic><offsets xml_i="47359" xml_f="47366" txt_i="23733" txt_f="23740"> = 147)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="47423" xml_f="47444" txt_i="23740" txt_f="23761">Postoperative death, </offsets><italic><offsets xml_i="47452" xml_f="47453" txt_i="23761" txt_f="23762">n</offsets></italic><offsets xml_i="47462" xml_f="47466" txt_i="23762" txt_f="23766"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47499" xml_f="47506" txt_i="23767" txt_f="23774">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47539" xml_f="47546" txt_i="23775" txt_f="23782">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="47588" xml_f="47596" txt_i="23783" txt_f="23791">Stroke, </offsets><italic><offsets xml_i="47604" xml_f="47605" txt_i="23791" txt_f="23792">n</offsets></italic><offsets xml_i="47614" xml_f="47618" txt_i="23792" txt_f="23796"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47651" xml_f="47658" txt_i="23797" txt_f="23804">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47691" xml_f="47698" txt_i="23805" txt_f="23812">1 (0.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="47740" xml_f="47754" txt_i="23813" txt_f="23827">Neurological, </offsets><italic><offsets xml_i="47762" xml_f="47763" txt_i="23827" txt_f="23828">n</offsets></italic><offsets xml_i="47772" xml_f="47776" txt_i="23828" txt_f="23832"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47809" xml_f="47818" txt_i="23833" txt_f="23842">18 (12.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47851" xml_f="47859" txt_i="23843" txt_f="23851">12 (8.2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="47901" xml_f="47922" txt_i="23852" txt_f="23873"> Type I (stroke, TIA)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47955" xml_f="47962" txt_i="23874" txt_f="23881">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="47995" xml_f="48002" txt_i="23882" txt_f="23889">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48044" xml_f="48080" txt_i="23890" txt_f="23926"> Type II (confusion, disorientation)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48113" xml_f="48122" txt_i="23927" txt_f="23936">15 (10.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48155" xml_f="48163" txt_i="23937" txt_f="23945">10 (6.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48205" xml_f="48243" txt_i="23946" txt_f="23984">Chest tube drainage at 12 h, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48276" xml_f="48285" txt_i="23985" txt_f="23994">701 (498)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48318" xml_f="48327" txt_i="23995" txt_f="24004">704 (448)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48369" xml_f="48382" txt_i="24005" txt_f="24018">Reoperation, </offsets><italic><offsets xml_i="48390" xml_f="48391" txt_i="24018" txt_f="24019">n</offsets></italic><offsets xml_i="48400" xml_f="48404" txt_i="24019" txt_f="24023"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48437" xml_f="48444" txt_i="24024" txt_f="24031">9 (6.5)</offsets><sup><offsets xml_i="48449" xml_f="48450" txt_i="24031" txt_f="24032">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="48489" xml_f="48497" txt_i="24033" txt_f="24041">13 (8.8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48539" xml_f="48548" txt_i="24042" txt_f="24051"> Bleeding</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48581" xml_f="48588" txt_i="24052" txt_f="24059">6 (4.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48621" xml_f="48629" txt_i="24060" txt_f="24068">11 (7.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48671" xml_f="48686" txt_i="24069" txt_f="24084"> LCOE/tamponade</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48719" xml_f="48726" txt_i="24085" txt_f="24092">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48759" xml_f="48766" txt_i="24093" txt_f="24100">1 (0.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48808" xml_f="48815" txt_i="24101" txt_f="24108"> Arrest</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48848" xml_f="48855" txt_i="24109" txt_f="24116">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48888" xml_f="48895" txt_i="24117" txt_f="24124">1 (0.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="48937" xml_f="48965" txt_i="24125" txt_f="24153"> Need for CPB at reoperation</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="48998" xml_f="49005" txt_i="24154" txt_f="24161">1 (0.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49038" xml_f="49045" txt_i="24162" txt_f="24169">1 (0.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49087" xml_f="49099" txt_i="24170" txt_f="24182">Arrhythmia, </offsets><italic><offsets xml_i="49107" xml_f="49108" txt_i="24182" txt_f="24183">n</offsets></italic><offsets xml_i="49117" xml_f="49121" txt_i="24183" txt_f="24187"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49154" xml_f="49163" txt_i="24188" txt_f="24197">55 (39.6)</offsets><sup><offsets xml_i="49168" xml_f="49169" txt_i="24197" txt_f="24198">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="49208" xml_f="49217" txt_i="24199" txt_f="24208">66 (44.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49259" xml_f="49279" txt_i="24209" txt_f="24229"> Atrial fibrillation</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49312" xml_f="49321" txt_i="24230" txt_f="24239">53 (38.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49354" xml_f="49363" txt_i="24240" txt_f="24249">64 (43.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49405" xml_f="49420" txt_i="24250" txt_f="24265"> Atrial flutter</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49453" xml_f="49460" txt_i="24266" txt_f="24273">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49493" xml_f="49500" txt_i="24274" txt_f="24281">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49542" xml_f="49553" txt_i="24282" txt_f="24293">Pneumonia, </offsets><italic><offsets xml_i="49561" xml_f="49562" txt_i="24293" txt_f="24294">n</offsets></italic><offsets xml_i="49571" xml_f="49575" txt_i="24294" txt_f="24298"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49608" xml_f="49617" txt_i="24299" txt_f="24308">15 (10.8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49650" xml_f="49658" txt_i="24309" txt_f="24317">14 (9.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49700" xml_f="49714" txt_i="24318" txt_f="24332">Tracheostomy, </offsets><italic><offsets xml_i="49722" xml_f="49723" txt_i="24332" txt_f="24333">n</offsets></italic><offsets xml_i="49732" xml_f="49736" txt_i="24333" txt_f="24337"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49769" xml_f="49776" txt_i="24338" txt_f="24345">4 (2.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49809" xml_f="49816" txt_i="24346" txt_f="24353">4 (2.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="49858" xml_f="49886" txt_i="24354" txt_f="24382">Any pulmonary complication, </offsets><italic><offsets xml_i="49894" xml_f="49895" txt_i="24382" txt_f="24383">n</offsets></italic><offsets xml_i="49904" xml_f="49908" txt_i="24383" txt_f="24387"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49941" xml_f="49950" txt_i="24388" txt_f="24397">33 (23.7)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="49983" xml_f="49992" txt_i="24398" txt_f="24407">34 (23.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50034" xml_f="50069" txt_i="24408" txt_f="24443">Creatinine day 4, mean (SD) (mg/dl)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50102" xml_f="50113" txt_i="24444" txt_f="24455">1.08 (0.35)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50146" xml_f="50157" txt_i="24456" txt_f="24467">1.10 (0.45)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50199" xml_f="50233" txt_i="24468" txt_f="24502">Creatinine peak, mean (SD) (mg/dl)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50266" xml_f="50277" txt_i="24503" txt_f="24514">1.34 (0.51)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50310" xml_f="50321" txt_i="24515" txt_f="24526">1.30 (0.54)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="50363" xml_f="50375" txt_i="24527" txt_f="24539">AKIN score, </offsets><italic><offsets xml_i="50383" xml_f="50384" txt_i="24539" txt_f="24540">n</offsets></italic><offsets xml_i="50393" xml_f="50397" txt_i="24540" txt_f="24544"> (%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50439" xml_f="50441" txt_i="24545" txt_f="24547"> 0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50474" xml_f="50484" txt_i="24548" txt_f="24558">121 (87.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50517" xml_f="50527" txt_i="24559" txt_f="24569">126 (85.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50569" xml_f="50571" txt_i="24570" txt_f="24572"> 1</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50604" xml_f="50612" txt_i="24573" txt_f="24581">13 (9.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50645" xml_f="50654" txt_i="24582" txt_f="24591">16 (10.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50696" xml_f="50698" txt_i="24592" txt_f="24594"> 2</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50731" xml_f="50738" txt_i="24595" txt_f="24602">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50771" xml_f="50777" txt_i="24603" txt_f="24609">0 (0%)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50819" xml_f="50821" txt_i="24610" txt_f="24612"> 3</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50854" xml_f="50861" txt_i="24613" txt_f="24620">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="50894" xml_f="50901" txt_i="24621" txt_f="24628">5 (3.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="50943" xml_f="50960" txt_i="24629" txt_f="24646">RRT requirement, </offsets><italic><offsets xml_i="50968" xml_f="50969" txt_i="24646" txt_f="24647">n</offsets></italic><offsets xml_i="50978" xml_f="50982" txt_i="24647" txt_f="24651"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51015" xml_f="51022" txt_i="24652" txt_f="24659">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51055" xml_f="51062" txt_i="24660" txt_f="24667">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="51104" xml_f="51128" txt_i="24668" txt_f="24692">Abdominal complication, </offsets><italic><offsets xml_i="51136" xml_f="51137" txt_i="24692" txt_f="24693">n</offsets></italic><offsets xml_i="51146" xml_f="51150" txt_i="24693" txt_f="24697"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51183" xml_f="51190" txt_i="24698" txt_f="24705">5 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51223" xml_f="51230" txt_i="24706" txt_f="24713">4 (2.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="51272" xml_f="51295" txt_i="24714" txt_f="24737"> Gastrointestinal bleed</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51328" xml_f="51335" txt_i="24738" txt_f="24745">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51368" xml_f="51375" txt_i="24746" txt_f="24753">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="51417" xml_f="51443" txt_i="24754" txt_f="24780"> Prolonged paralytic ileus</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51476" xml_f="51481" txt_i="24781" txt_f="24786">0 (0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51514" xml_f="51521" txt_i="24787" txt_f="24794">2 (1.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="51563" xml_f="51573" txt_i="24795" txt_f="24805"> Diarrhoea</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51606" xml_f="51613" txt_i="24806" txt_f="24813">3 (2.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51646" xml_f="51651" txt_i="24814" txt_f="24819">0 (0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="51693" xml_f="51712" txt_i="24820" txt_f="24839">Sternal infection, </offsets><italic><offsets xml_i="51720" xml_f="51721" txt_i="24839" txt_f="24840">n</offsets></italic><offsets xml_i="51730" xml_f="51734" txt_i="24840" txt_f="24844"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51767" xml_f="51774" txt_i="24845" txt_f="24852">5 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51807" xml_f="51814" txt_i="24853" txt_f="24860">5 (3.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="51856" xml_f="51889" txt_i="24861" txt_f="24894"> Superficial infection/dehiscence</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51922" xml_f="51929" txt_i="24895" txt_f="24902">5 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="51962" xml_f="51969" txt_i="24903" txt_f="24910">4 (2.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52011" xml_f="52044" txt_i="24911" txt_f="24944"> Deep infection requiring surgery</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52077" xml_f="52082" txt_i="24945" txt_f="24950">0 (0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52115" xml_f="52122" txt_i="24951" txt_f="24958">1 (0.7)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52164" xml_f="52195" txt_i="24959" txt_f="24990">Any treated infective episode, </offsets><italic><offsets xml_i="52203" xml_f="52204" txt_i="24990" txt_f="24991">n</offsets></italic><offsets xml_i="52213" xml_f="52217" txt_i="24991" txt_f="24995"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52250" xml_f="52259" txt_i="24996" txt_f="25005">27 (19.4)</offsets><sup><offsets xml_i="52264" xml_f="52265" txt_i="25005" txt_f="25006">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="52304" xml_f="52313" txt_i="25007" txt_f="25016">25 (17.0)</offsets></td></tr><tr><td colspan="3" rowspan="1"><offsets xml_i="52355" xml_f="52385" txt_i="25017" txt_f="25047">Transfusion, mean (SD) (units)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52427" xml_f="52433" txt_i="25048" txt_f="25054"> Blood</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52466" xml_f="52477" txt_i="25055" txt_f="25066">2.26 (2.62)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52510" xml_f="52521" txt_i="25067" txt_f="25078">2.02 (2.58)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52563" xml_f="52573" txt_i="25079" txt_f="25089"> Platelets</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52606" xml_f="52617" txt_i="25090" txt_f="25101">0.82 (1.30)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52650" xml_f="52661" txt_i="25102" txt_f="25113">0.85 (1.18)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52703" xml_f="52723" txt_i="25114" txt_f="25134"> Fresh frozen plasma</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52756" xml_f="52767" txt_i="25135" txt_f="25146">1.89 (2.55)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52800" xml_f="52811" txt_i="25147" txt_f="25158">1.85 (2.64)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="52853" xml_f="52892" txt_i="25159" txt_f="25198">Fluid volume in 12 h, mean (SD) (ml/kg)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52925" xml_f="52936" txt_i="25199" txt_f="25210">67.4 (27.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="52969" xml_f="52980" txt_i="25211" txt_f="25222">62.7 (31.3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53022" xml_f="53033" txt_i="25223" txt_f="25234">Discharge, </offsets><italic><offsets xml_i="53041" xml_f="53042" txt_i="25234" txt_f="25235">n</offsets></italic><offsets xml_i="53051" xml_f="53055" txt_i="25235" txt_f="25239"> (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53088" xml_f="53098" txt_i="25240" txt_f="25250">137 (98.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53131" xml_f="53141" txt_i="25251" txt_f="25261">145 (98.6)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53183" xml_f="53188" txt_i="25262" txt_f="25267"> Home</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53221" xml_f="53231" txt_i="25268" txt_f="25278">130 (93.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53264" xml_f="53274" txt_i="25279" txt_f="25289">138 (93.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53316" xml_f="53330" txt_i="25290" txt_f="25304"> Convalescence</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53363" xml_f="53370" txt_i="25305" txt_f="25312">5 (3.6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53403" xml_f="53410" txt_i="25313" txt_f="25320">6 (4.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="53452" xml_f="53480" txt_i="25321" txt_f="25349"> Another hospital/department</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53513" xml_f="53520" txt_i="25350" txt_f="25357">2 (1.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="53553" xml_f="53560" txt_i="25358" txt_f="25365">1 (0.7)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="TN11"><p><offsets xml_i="53620" xml_f="53806" txt_i="25366" txt_f="25552">TIA: transient ischaemic attack; LCOE: low cardiac output episode; CPB: cardiopulmonary bypass; AKIN: Acute Kidney Injury Network; RRT: renal replacement therapy; SD: standard deviation.</offsets></p></fn><fn id="TN12"><p><sup><offsets xml_i="53837" xml_f="53838" txt_i="25553" txt_f="25554">a</offsets></sup><offsets xml_i="53844" xml_f="53885" txt_i="25554" txt_f="25595">Not significant with Fisher's exact test.</offsets></p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s3d"><title><offsets xml_i="53962" xml_f="53982" txt_i="25599" txt_f="25619">Metabolomic analysis</offsets></title><p><offsets xml_i="53993" xml_f="54096" txt_i="25620" txt_f="25723">Polar extracts from preischaemic left ventricular biopsies were analysed from 43 patients (perhexiline </offsets><italic><offsets xml_i="54104" xml_f="54105" txt_i="25723" txt_f="25724">n</offsets></italic><offsets xml_i="54114" xml_f="54129" txt_i="25724" txt_f="25739"> = 22, control </offsets><italic><offsets xml_i="54137" xml_f="54138" txt_i="25739" txt_f="25740">n</offsets></italic><offsets xml_i="54147" xml_f="54402" txt_i="25740" txt_f="25995"> = 21). All biopsies from the perhexiline group were from patients above the lower end of the therapeutic range (median 0.36 mg/l, IQR 0.24–0.58). The median spectral relative standard deviation, a benchmark to assess the reproducibility in metabolomics [</offsets><xref rid="EZU238C21" ref-type="bibr"><offsets xml_i="54440" xml_f="54442" txt_i="25995" txt_f="25997">21</offsets></xref><offsets xml_i="54449" xml_f="55129" txt_i="25997" txt_f="26677">], for each sample analysed in triplicate by MS was relatively small and consistent across all samples (mean 11.6%, SD 1.6%). The final intensity matrix after data processing consisted of 4039 peak intensity measurements for each sample. All peaks were examined using univariate statistics to determine if any intensity changed significantly in response to perhexiline treatment. No significant peak intensity changes were found (FDR 5%). Multivariate PCA was used to reduce the dimensionality of the data and visualize the metabolic similarities and differences between the two groups; the plot of PCA scores did not show any metabolic effects due to perhexiline treatment (Fig. </offsets><xref ref-type="fig" rid="EZU238F4"><offsets xml_i="55165" xml_f="55166" txt_i="26677" txt_f="26678">4</offsets></xref><offsets xml_i="55173" xml_f="55386" txt_i="26678" txt_f="26891">). The clustering of the QC samples demonstrates the consistency in instrument performance over time. Additionally, PLS-DA was conducted to maximize the separation of the metabolic profiles of the two groups (see </offsets><ext-link ext-link-type="uri" xlink:href="http://ejcts.oxfordjournals.org/lookup/suppl/doi:10.1093/ejcts/ezu238/-/DC1"><offsets xml_i="55505" xml_f="55527" txt_i="26891" txt_f="26913">Supplementary material</offsets></ext-link><offsets xml_i="55538" xml_f="55803" txt_i="26913" txt_f="27178">). The control and treatment samples were minimally separated, and the associated mean classification error rates of the model for predicting class membership were high at 43 and 47%, respectively, suggesting no metabolic differences between groups. More than 200 m</offsets><italic><offsets xml_i="55811" xml_f="55813" txt_i="27178" txt_f="27180">/z</offsets></italic><offsets xml_i="55822" xml_f="56011" txt_i="27180" txt_f="27369"> measurements in the FT-ICR MS dataset were assigned to at least one putative named metabolite including ATP, creatine, phosphocreatine, glycolytic and citric acid cycle intermediates (see </offsets><ext-link ext-link-type="uri" xlink:href="http://ejcts.oxfordjournals.org/lookup/suppl/doi:10.1093/ejcts/ezu238/-/DC1"><offsets xml_i="56130" xml_f="56152" txt_i="27369" txt_f="27391">Supplementary material</offsets></ext-link><offsets xml_i="56163" xml_f="56166" txt_i="27391" txt_f="27394">).
</offsets><fig id="EZU238F4" position="float"><label><offsets xml_i="56209" xml_f="56218" txt_i="27394" txt_f="27403">Figure 4:</offsets></label><caption><p><offsets xml_i="56238" xml_f="56658" txt_i="27403" txt_f="27823">Principal components analysis scores plot from negative ion Fourier transform ion cyclotron resonance mass spectra of left ventricular extracts: 21 control samples (blue) and 22 perhexiline samples (red), shows no metabolic response to perhexiline along the PC1 and PC2 axes. All eight quality control samples (X) are in a narrow cluster, confirming the consistency of mass spectrometry instrument performance over time.</offsets></p></caption><graphic xlink:href="ezu23804"></graphic></fig></p></sec></sec><sec sec-type="discussion" id="s4"><title><offsets xml_i="56777" xml_f="56787" txt_i="27827" txt_f="27837">DISCUSSION</offsets></title><p><offsets xml_i="56798" xml_f="57811" txt_i="27838" txt_f="28851">In this double-blind, randomized, placebo-controlled trial of preoperative oral perhexiline as an adjunct to cold blood cardioplegia for myocardial protection during CABG, there was no effect on the primary end-point, the incidence of a LCOE. This was confirmed in a propensity score-matched analysis in which patients in the treatment group who were below the therapeutic range were excluded. In addition, there was no difference in the use of inotropes in the first 6 h or the incidence of myocardial injury determined by troponin release or significant ECG changes between groups. Indeed, cardiac index was found to be lower in the treatment arm compared with controls both prior to ischaemia and at 6 h after release of the aortic cross-clamp. On studying the polar metabolome of the left ventricle prior to ischaemia using MS-based metabolomics, we found that the metabolic profiles of patients on perhexiline, with confirmed therapeutic plasma levels, were indistinguishable from those in the placebo group.</offsets></p><p><offsets xml_i="57818" xml_f="58090" txt_i="28852" txt_f="29124">Metabolic therapy provides an opportunity to improve myocardial protection by inducing a shift in substrate utilization from fatty acids to glucose, thereby increasing the efficiency of energy production and reducing the harmful effects of β-oxidation during reperfusion [</offsets><xref rid="EZU238C4" ref-type="bibr"><offsets xml_i="58127" xml_f="58128" txt_i="29124" txt_f="29125">4</offsets></xref><offsets xml_i="58135" xml_f="58723" txt_i="29125" txt_f="29713">]. The most extensively studied metabolic strategy is altering the availability and use of substrates using intravenous GIK solution. Insulin has multiple metabolic and non-metabolic effects on the myocardium but their relative importance is unclear. These include suppression of lipolysis with reduced uptake and β-oxidation of fatty acids; increased glucose flux, myocardial oxygen efficiency and glycolytic ATP production; replenishment of citric acid cycle intermediates via anaplerosis; and activation of prosurvival reperfusion injury salvage kinases (RISK) including Akt and AMPK [</offsets><xref rid="EZU238C7" ref-type="bibr"><offsets xml_i="58760" xml_f="58761" txt_i="29713" txt_f="29714">7</offsets></xref><offsets xml_i="58768" xml_f="58930" txt_i="29714" txt_f="29876">]. GIK has been shown to improve postoperative haemodynamics, decrease inotrope requirements and reduce myocardial injury in patients undergoing cardiac surgery [</offsets><xref rid="EZU238C6" ref-type="bibr"><offsets xml_i="58967" xml_f="58968" txt_i="29876" txt_f="29877">6</offsets></xref><offsets xml_i="58975" xml_f="58977" txt_i="29877" txt_f="29879">, </offsets><xref rid="EZU238C7" ref-type="bibr"><offsets xml_i="59014" xml_f="59015" txt_i="29879" txt_f="29880">7</offsets></xref><offsets xml_i="59022" xml_f="59024" txt_i="29880" txt_f="29882">, </offsets><xref rid="EZU238C22" ref-type="bibr"><offsets xml_i="59062" xml_f="59064" txt_i="29882" txt_f="29884">22</offsets></xref><offsets xml_i="59071" xml_f="59364" txt_i="29884" txt_f="30177">], but has not been widely adopted principally due to practical difficulties in its administration. While perhexiline has not previously been studied as an adjunct to myocardial protection in cardiac surgery, it has been shown to be clinically effective in the treatment of refractory angina [</offsets><xref rid="EZU238C8" ref-type="bibr"><offsets xml_i="59401" xml_f="59402" txt_i="30177" txt_f="30178">8</offsets></xref><offsets xml_i="59409" xml_f="59437" txt_i="30178" txt_f="30206">], chronic cardiac failure [</offsets><xref rid="EZU238C9" ref-type="bibr"><offsets xml_i="59474" xml_f="59475" txt_i="30206" txt_f="30207">9</offsets></xref><offsets xml_i="59482" xml_f="59529" txt_i="30207" txt_f="30254">] and symptomatic hypertrophic cardiomyopathy [</offsets><xref rid="EZU238C10" ref-type="bibr"><offsets xml_i="59567" xml_f="59569" txt_i="30254" txt_f="30256">10</offsets></xref><offsets xml_i="59576" xml_f="59735" txt_i="30256" txt_f="30415">]. Its mechanism of action has been widely accepted as inhibition of mitochondrial CPT-1, leading to reduced uptake and β-oxidation of long-chain fatty acids [</offsets><xref rid="EZU238C12" ref-type="bibr"><offsets xml_i="59773" xml_f="59775" txt_i="30415" txt_f="30417">12</offsets></xref><offsets xml_i="59782" xml_f="60029" txt_i="30417" txt_f="30664">]. A recent proteomic and metabolomic study in a murine model suggested that perhexiline activates the pyruvate dehydrogenase complex and may cause a complex rebalancing of carbon and nucleotide phosphate fluxes to increase metabolic flexibility [</offsets><xref rid="EZU238C23" ref-type="bibr"><offsets xml_i="60067" xml_f="60069" txt_i="30664" txt_f="30666">23</offsets></xref><offsets xml_i="60076" xml_f="60532" txt_i="30666" txt_f="31122">]. However, our metabolomic analysis demonstrates that, in patients with ischaemic heart disease undergoing cardiac surgery, perhexiline has no significant effect on the polar myocardial metabolome with no change in the intermediates of energy transfer, glycolysis or the citric acid cycle. This lack of up-regulation in glucose metabolism may account for the lack of clinical benefit in this trial and suggests that the mechanism of action of perhexiline </offsets><italic><offsets xml_i="60540" xml_f="60547" txt_i="31122" txt_f="31129">in vivo</offsets></italic><offsets xml_i="60556" xml_f="60837" txt_i="31129" txt_f="31410"> in humans may not be primarily metabolic. The possibility that perhexiline acts via a CPT-independent pathway has previously been raised following the observation that there is a temporal dissociation between its effects on cardiac efficiency and metabolism in a rat heart model [</offsets><xref rid="EZU238C24" ref-type="bibr"><offsets xml_i="60875" xml_f="60877" txt_i="31410" txt_f="31412">24</offsets></xref><offsets xml_i="60884" xml_f="61127" txt_i="31412" txt_f="31655">]. Recent work has shown that it suppresses expression of thioredoxin-interacting protein (TXNIP), the key regulator of the antioxidant thioredoxin system, and increases expression of the energy sensor AMPK and its downstream effector PGC-1α [</offsets><xref rid="EZU238C25" ref-type="bibr"><offsets xml_i="61165" xml_f="61167" txt_i="31655" txt_f="31657">25</offsets></xref><offsets xml_i="61174" xml_f="61468" txt_i="31657" txt_f="31951">], although the relevance of these observations remains to be proven. While its predominant mechanism of action in non-surgical patients remains unconfirmed, we found neither an improvement in contractility at any time point nor a reduction in myocardial injury following ischaemia–reperfusion.</offsets></p><p><offsets xml_i="61475" xml_f="61665" txt_i="31952" txt_f="32142">Patients treated with perhexiline had a lower cardiac index prior to ischaemia although the mechanisms underlying this finding are unknown. Despite a weak calcium channel inhibitory effect [</offsets><xref rid="EZU238C11" ref-type="bibr"><offsets xml_i="61703" xml_f="61705" txt_i="32142" txt_f="32144">11</offsets></xref><offsets xml_i="61712" xml_f="62621" txt_i="32144" txt_f="33053">], perhexiline has not previously been found to be negatively inotropic although none of the previous studies involved anaesthesia or surgery. Plasma free fatty acids prior to ischaemia were significantly higher in the perhexiline group than the control group; high levels of fatty acids are known to reduce cardiac efficiency although there was no correlation between plasma free fatty acids and preischaemic cardiac index. In the design and conduct of the trial, randomization was stratified for left ventricular function, although it was not precisely quantified on echocardiogram prior to commencing the trial therapy. All patients in whom the primary end-point was available were analysed on an intention-to-treat basis and no differences between groups were observed for the primary end-point, other secondary outcomes apart from the cardiac index, safety end-points or any other postoperative variable.</offsets></p><p><offsets xml_i="62628" xml_f="62771" txt_i="33054" txt_f="33197">One of the limitations of perhexiline is the marked interindividual variation in its metabolism mainly due to genetic polymorphisms of CYP2D6 [</offsets><xref rid="EZU238C11" ref-type="bibr"><offsets xml_i="62809" xml_f="62811" txt_i="33197" txt_f="33199">11</offsets></xref><offsets xml_i="62818" xml_f="63784" txt_i="33199" txt_f="34165">]. The dosing regimen used in this trial attempted to achieve prompt but effective loading with perhexiline in the community with a low incidence of toxicity, especially in poor metabolizers of the drug. We found that ∼27% of the perhexiline group were below the lower threshold of the therapeutic range (0.15 mg/l) at the time of surgery but there was no correlation with length of therapy, suggesting that the minimum period of loading was sufficient. These sub-therapeutic patients comprised all of those found to be ultrarapid metabolizers of perhexiline plus some of the patients who had reported side effects and were either known or presumed to have stopped taking the drug. While this failure to attain a therapeutic concentration at the time of surgery is a limitation of perhexiline use, the comparison of therapeutic patients with propensity score-matched controls confirmed that perhexiline had no benefit in reducing the incidence of LCOE in this trial.</offsets></p><p><offsets xml_i="63791" xml_f="64426" txt_i="34166" txt_f="34801">In conclusion, the addition of oral perhexiline as an adjunct to cardioplegia in patients undergoing CABG did not improve clinical or biochemical end-points of myocardial protection or any other outcome measures, and was associated with a reduction in the perioperative cardiac index. Therefore, preoperative perhexiline does not improve the outcomes of patients undergoing cardiac surgery and may in fact impair cardiac function in the perioperative period, increasing the need for inotropic support. We also present novel human data suggesting that perhexiline has no significant effect on the MS-visible polar myocardial metabolome </offsets><italic><offsets xml_i="64434" xml_f="64441" txt_i="34801" txt_f="34808">in vivo</offsets></italic><xref rid="EZU238C24" ref-type="bibr"><offsets xml_i="64488" xml_f="64490" txt_i="34808" txt_f="34810">24</offsets></xref><offsets xml_i="64497" xml_f="64571" txt_i="34810" txt_f="34884">] and may explain the lack of clinical benefit observed following surgery.</offsets></p></sec><sec id="s5"><title><offsets xml_i="64601" xml_f="64623" txt_i="34886" txt_f="34908">SUPPLEMENTARY MATERIAL</offsets></title><p><ext-link ext-link-type="uri" xlink:href="http://ejcts.oxfordjournals.org/lookup/suppl/doi:10.1093/ejcts/ezu238/-/DC1"><offsets xml_i="64753" xml_f="64792" txt_i="34909" txt_f="34948">Supplementary material is available at </offsets><italic><offsets xml_i="64800" xml_f="64805" txt_i="34948" txt_f="34953">EJCTS</offsets></italic><offsets xml_i="64814" xml_f="64822" txt_i="34953" txt_f="34961"> online.</offsets></ext-link></p></sec><sec id="s6"><title><offsets xml_i="64863" xml_f="64870" txt_i="34963" txt_f="34970">Funding</offsets></title><p><offsets xml_i="64881" xml_f="64912" txt_i="34971" txt_f="35002">This work was supported by the </offsets><funding-source id="cs1" rid="cn1"><offsets xml_i="64947" xml_f="64971" txt_i="35002" txt_f="35026">British Heart Foundation</offsets></funding-source><offsets xml_i="64988" xml_f="65004" txt_i="35026" txt_f="35042"> (grant numbers </offsets><award-id id="cn1" rid="cs1"><offsets xml_i="65033" xml_f="65048" txt_i="35042" txt_f="35057">PG/06/044/20703</offsets></award-id><offsets xml_i="65059" xml_f="65061" txt_i="35057" txt_f="35059">, </offsets><award-id id="cn2" rid="cs2"><offsets xml_i="65090" xml_f="65105" txt_i="35059" txt_f="35074">PG/10/036/28341</offsets></award-id><offsets xml_i="65116" xml_f="65126" txt_i="35074" txt_f="35084">) and the </offsets><funding-source id="cs2" rid="cn2"><offsets xml_i="65161" xml_f="65181" txt_i="35084" txt_f="35104">Sussex Heart Charity</offsets></funding-source><offsets xml_i="65198" xml_f="65236" txt_i="35104" txt_f="35142">. The clinical trial was sponsored by </offsets><funding-source><offsets xml_i="65252" xml_f="65304" txt_i="35142" txt_f="35194">University Hospitals Birmingham NHS Foundation Trust</offsets></funding-source><offsets xml_i="65321" xml_f="65436" txt_i="35194" txt_f="35309">. Funding to pay the Open Access publication charges for this article was provided by the British Heart Foundation.</offsets></p><p><bold><offsets xml_i="65449" xml_f="65470" txt_i="35310" txt_f="35331">Conflict of interest:</offsets></bold><offsets xml_i="65477" xml_f="65860" txt_i="35331" txt_f="35714"> Michael P. Frenneaux is inventor of method of use patents for perhexiline in heart muscle diseases. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree with the manuscript as written. Neither the funders nor the sponsor had any intellectual input into the design, analysis, report or submission for publication.</offsets></p></sec><offsets xml_i="65870" xml_f="65871" txt_i="35716" txt_f="35717">
</offsets><sec sec-type="supplementary-material"><offsets xml_i="65910" xml_f="65911" txt_i="35717" txt_f="35718">
</offsets><title><offsets xml_i="65918" xml_f="65940" txt_i="35718" txt_f="35740">Supplementary Material</offsets></title><offsets xml_i="65948" xml_f="65949" txt_i="35741" txt_f="35742">
</offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="66010" xml_f="66011" txt_i="35742" txt_f="35743">
</offsets><caption><offsets xml_i="66020" xml_f="66021" txt_i="35743" txt_f="35744">
</offsets><title><offsets xml_i="66028" xml_f="66046" txt_i="35744" txt_f="35762">Supplementary Data</offsets></title><offsets xml_i="66054" xml_f="66055" txt_i="35763" txt_f="35764">
</offsets></caption><offsets xml_i="66065" xml_f="66066" txt_i="35764" txt_f="35765">
</offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_47_3_464__index.html"></media><offsets xml_i="66156" xml_f="66157" txt_i="35765" txt_f="35766">
</offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_ezu238_ezu238supp.docx"></media><offsets xml_i="66287" xml_f="66288" txt_i="35766" txt_f="35767">
</offsets></supplementary-material><offsets xml_i="66313" xml_f="66314" txt_i="35767" txt_f="35768">
</offsets></sec><offsets xml_i="66320" xml_f="66321" txt_i="35769" txt_f="35770">
</offsets></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>The other anaesthetists in the study group were: Peter Townsend, Deborah J. Turfrey, Tessa Oelofse, David W. Riddington, Mark P. Wilkes, Harjot Singh, Suneel Desai, Muzaffar H. Faroqui, Tariq Hoth, Anwar A. Karim, Craig McGrath and Nevil P. Hutchinson. We also thank John D. Horowitz, University of Adelaide, for advice on conducting the trial and Benedetta C. Sallustio <italic>et al.</italic> at The Queen Elizabeth Hospital, Adelaide, Australia, for performing the serum perhexiline analysis.</p></ack><ref-list><title>REFERENCES</title><ref id="EZU238C1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bridgewater</surname><given-names>B</given-names></name><name><surname>Keogh</surname><given-names>BE</given-names></name><name><surname>Kinsman</surname><given-names>R</given-names></name><name><surname>Walton</surname><given-names>P</given-names></name></person-group><article-title>Sixth National Adult Cardiac Surgery Database Report 2008</article-title><year>2009</year><publisher-loc>Henley-on-Thames</publisher-loc><publisher-name>Dendrite Clinical Systems, Ltd</publisher-name><comment>Demonstrating Quality</comment></element-citation></ref><ref id="EZU238C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenst</surname><given-names>T</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>Yau</surname><given-names>TM</given-names></name><name><surname>Maganti</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name></person-group><article-title>Relation between aortic cross-clamp time and mortality—not as straightforward as expected</article-title><source>Eur J Cardiothorac Surg</source><year>2008</year><volume>33</volume><fpage>660</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18272383</pub-id></element-citation></ref><ref id="EZU238C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fremes</surname><given-names>SE</given-names></name><name><surname>Tamariz</surname><given-names>MG</given-names></name><name><surname>Abramov</surname><given-names>D</given-names></name><name><surname>Christakis</surname><given-names>GT</given-names></name><name><surname>Sever</surname><given-names>JY</given-names></name><name><surname>Sykora</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Late results of the Warm Heart Trial: the influence of nonfatal cardiac events on late survival</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>III339</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">11082411</pub-id></element-citation></ref><ref id="EZU238C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenst</surname><given-names>T</given-names></name><name><surname>Bugger</surname><given-names>H</given-names></name><name><surname>Schwarzer</surname><given-names>M</given-names></name><name><surname>Faerber</surname><given-names>G</given-names></name><name><surname>Borger</surname><given-names>MA</given-names></name><name><surname>Mohr</surname><given-names>FW</given-names></name></person-group><article-title>Three good reasons for heart surgeons to understand cardiac metabolism</article-title><source>Eur J Cardiothorac Surg</source><year>2008</year><volume>33</volume><fpage>862</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">18353669</pub-id></element-citation></ref><ref id="EZU238C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopaschuk</surname><given-names>GD</given-names></name><name><surname>Ussher</surname><given-names>JR</given-names></name><name><surname>Folmes</surname><given-names>CD</given-names></name><name><surname>Jaswal</surname><given-names>JS</given-names></name><name><surname>Stanley</surname><given-names>WC</given-names></name></person-group><article-title>Myocardial fatty acid metabolism in health and disease</article-title><source>Physiol Rev</source><year>2010</year><volume>90</volume><fpage>207</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">20086077</pub-id></element-citation></ref><ref id="EZU238C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>DW</given-names></name><name><surname>Pagano</surname><given-names>D</given-names></name><name><surname>Bonser</surname><given-names>RS</given-names></name><name><surname>Rooney</surname><given-names>SJ</given-names></name><name><surname>Graham</surname><given-names>TR</given-names></name><name><surname>Wilson</surname><given-names>IC</given-names></name><etal></etal></person-group><article-title>Improved myocardial protection during coronary artery surgery with glucose-insulin-potassium: a randomized controlled trial</article-title><source>J Thorac Cardiovasc Surg</source><year>2006</year><volume>131</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16399292</pub-id></element-citation></ref><ref id="EZU238C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>NJ</given-names></name><name><surname>Ashrafian</surname><given-names>H</given-names></name><name><surname>Drury</surname><given-names>NE</given-names></name><name><surname>Ranasinghe</surname><given-names>AM</given-names></name><name><surname>Contractor</surname><given-names>H</given-names></name><name><surname>Isackson</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) Trial</article-title><source>Circulation</source><year>2011</year><volume>123</volume><fpage>170</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21200004</pub-id></element-citation></ref><ref id="EZU238C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>PL</given-names></name><name><surname>Beamer</surname><given-names>AD</given-names></name><name><surname>McGowan</surname><given-names>N</given-names></name><name><surname>Cantillon</surname><given-names>CO</given-names></name><name><surname>Benfell</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>RA</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent.</article-title><source>Circulation</source><year>1990</year><volume>81</volume><fpage>1260</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2180591</pub-id></element-citation></ref><ref id="EZU238C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Campbell</surname><given-names>R</given-names></name><name><surname>Scheuermann-Freestone</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Gunaruwan</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>3280</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16301359</pub-id></element-citation></ref><ref id="EZU238C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abozguia</surname><given-names>K</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><name><surname>McKenna</surname><given-names>W</given-names></name><name><surname>Phan</surname><given-names>TT</given-names></name><name><surname>Nallur-Shivu</surname><given-names>G</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>1562</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20921440</pub-id></element-citation></ref><ref id="EZU238C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>JD</given-names></name><name><surname>Sia</surname><given-names>ST</given-names></name><name><surname>Macdonald</surname><given-names>PS</given-names></name><name><surname>Goble</surname><given-names>AJ</given-names></name><name><surname>Louis</surname><given-names>WJ</given-names></name></person-group><article-title>Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics</article-title><source>Int J Cardiol</source><year>1986</year><volume>13</volume><fpage>219</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">3793279</pub-id></element-citation></ref><ref id="EZU238C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>JA</given-names></name><name><surname>Unger</surname><given-names>SA</given-names></name><name><surname>Horowitz</surname><given-names>JD</given-names></name></person-group><article-title>Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone</article-title><source>Biochem Pharmacol</source><year>1996</year><volume>52</volume><fpage>273</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">8694852</pub-id></element-citation></ref><ref id="EZU238C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>JL</given-names></name><name><surname>Atherton</surname><given-names>H</given-names></name><name><surname>Shockcor</surname><given-names>J</given-names></name><name><surname>Atzori</surname><given-names>L</given-names></name></person-group><article-title>Metabolomics as a tool for cardiac research</article-title><source>Nat Rev Cardiol</source><year>2011</year><volume>8</volume><fpage>630</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21931361</pub-id></element-citation></ref><ref id="EZU238C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Southam</surname><given-names>AD</given-names></name><name><surname>Hines</surname><given-names>A</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>High-throughput tissue extraction protocol for NMR- and MS-based metabolomics</article-title><source>Anal Biochem</source><year>2008</year><volume>372</volume><fpage>204</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17963684</pub-id></element-citation></ref><ref id="EZU238C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>RJM</given-names></name><name><surname>Southam</surname><given-names>AD</given-names></name><name><surname>Sommer</surname><given-names>U</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>Characterization of isotopic abundance measurements in high resolution FT-ICR and Orbitrap mass spectra for improved confidence of metabolite identification</article-title><source>Anal Chem</source><year>2011</year><volume>83</volume><fpage>3737</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21466230</pub-id></element-citation></ref><ref id="EZU238C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Southam</surname><given-names>AD</given-names></name><name><surname>Payne</surname><given-names>TG</given-names></name><name><surname>Cooper</surname><given-names>HJ</given-names></name><name><surname>Arvanitis</surname><given-names>TN</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>Dynamic range and mass accuracy of wide-scan direct infusion nanoelectrospray Fourier transform ion cyclotron resonance mass spectrometry-based metabolomics increased by the spectral stitching method</article-title><source>Anal Chem</source><year>2007</year><volume>79</volume><fpage>4595</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">17511421</pub-id></element-citation></ref><ref id="EZU238C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>TG</given-names></name><name><surname>Southam</surname><given-names>AD</given-names></name><name><surname>Arvanitis</surname><given-names>TN</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>A signal filtering method for improved quantification and noise discrimination in Fourier transform ion cyclotron resonance mass spectrometry-based metabolomics data</article-title><source>J Am Soc Mass Spectrom</source><year>2009</year><volume>20</volume><fpage>1087</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">19269189</pub-id></element-citation></ref><ref id="EZU238C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrydziuszko</surname><given-names>O</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>Missing values in mass spectrometry based metabolomics: an undervalued step in the data processing pipeline</article-title><source>Metabolomics</source><year>2012</year><volume>(Suppl 8)</volume><fpage>161</fpage><lpage>74</lpage></element-citation></ref><ref id="EZU238C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>RJM</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>MI-Pack: increased confidence of metabolite identification in mass spectra by integrating accurate masses and metabolic pathways</article-title><source>Chemom Intell Lab Syst</source><year>2010</year><volume>104</volume><fpage>75</fpage><lpage>82</lpage></element-citation></ref><ref id="EZU238C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the false discovery rate—a practical and powerful approach to multiple testing</article-title><source>J R Stat Soc Ser B Methodol</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage></element-citation></ref><ref id="EZU238C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>HM</given-names></name><name><surname>Ekman</surname><given-names>DR</given-names></name><name><surname>Collette</surname><given-names>TW</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name></person-group><article-title>Spectral relative standard deviation: a practical benchmark in metabolomics</article-title><source>Analyst</source><year>2009</year><volume>134</volume><fpage>478</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">19238283</pub-id></element-citation></ref><ref id="EZU238C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>AM</given-names></name><name><surname>Xiao</surname><given-names>YB</given-names></name><name><surname>Weng</surname><given-names>YG</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name></person-group><article-title>Glucose-insulin-potassium therapy in adult patients undergoing cardiac surgery: a meta-analysis</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><fpage>192</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21075642</pub-id></element-citation></ref><ref id="EZU238C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Dwyer</surname><given-names>J</given-names></name><name><surname>Langley</surname><given-names>SR</given-names></name><name><surname>Mayr</surname><given-names>U</given-names></name><name><surname>Xing</surname><given-names>Q</given-names></name><name><surname>Drozdov</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome</article-title><source>J Mol Cell Cardiol</source><year>2013</year><volume>55</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">23277191</pub-id></element-citation></ref><ref id="EZU238C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unger</surname><given-names>SA</given-names></name><name><surname>Kennedy</surname><given-names>JA</given-names></name><name><surname>McFadden-Lewis</surname><given-names>K</given-names></name><name><surname>Minerds</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>GA</given-names></name><name><surname>Horowitz</surname><given-names>JD</given-names></name></person-group><article-title>Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium</article-title><source>J Cardiovasc Pharmacol</source><year>2005</year><volume>46</volume><fpage>849</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16306812</pub-id></element-citation></ref><ref id="EZU238C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>DT</given-names></name><name><surname>Drury</surname><given-names>NE</given-names></name><name><surname>Frenneaux</surname><given-names>M</given-names></name><name><surname>Pagano</surname><given-names>D</given-names></name><name><surname>Horowitz</surname><given-names>JD</given-names></name></person-group><article-title>How does perhexiline modulate myocardial energetics and ameliorate redox stress?</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>14461</fpage><comment>Abstract</comment></element-citation></ref></ref-list></back></article>